



Clinical trial results:

International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ.

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2004-003992-35 |
| Trial protocol | SE |
| Global end of trial date | 31 May 2021 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 12 May 2022 |
| First version publication date | 12 May 2022 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | MREC02/8/71 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|----------------|
| ISRCTN number | ISRCTN37546358 |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Queen Mary University London |
| Sponsor organisation address | Wolfson Institute of Population Health, London, United Kingdom, EC1M 6BQ |
| Public contact | Professor Jack Cuzick, Queen Mary University London, j.cuzick@qmul.ac.uk |
| Scientific contact | Professor Jack Cuzick, Queen Mary University London, j.cuzick@qmul.ac.uk |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-------------|
| Analysis stage | Final |
| Date of interim/final analysis | 31 May 2021 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 31 May 2021 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

To determine if anastrozole is at least as effective as tamoxifen in local control and prevention of contralateral disease in women with locally excised ER or PgR+ve DCIS and to compare side effect profiles of tamoxifen and anastrozole.

Protection of trial subjects:

Eligibility criteria were risk-based, varied by age, and defined in the protocol to ensure protection of participants. Participants were informed of potential side-effects prior to study entry and if new side-effects were added to the Summary of Product Characteristics (SmPC) after randomisation, women were informed at their next clinic appointment. Women were informed of their right to withdraw at any point.

Only post-menopausal women diagnosed with locally excised, hormone-receptor-positive DCIS were eligible. Women aged 60 without a uterus were eligible if they had FSH levels >30 IU/L and if taking HRT, an 8 week wash-out period was required prior to a FSH test being performed. Due to potential concerns over the effects of the trial interventions on pre-existing conditions associated with low bone mineral density, women with osteoporosis were excluded and a DXA scan and spinal radiograph within the last two years was required prior to randomisation.

Advice on maintaining healthy bones was offered to women in the trial. Treatment with bisphosphonates was considered where necessary. If serious menopausal symptoms developed during treatment, management followed a protocolised approach including details on when to reduce dosing of the trial intervention. Circumstances which indicated cessation of the IMP were listed in the protocol. A codebreak procedure to unblind clinicians and participants was active throughout the study. Adverse events were collected and reviewed regularly by the Trial team and Steering Committee.

Background therapy: -

Evidence for comparator:

IBIS-II (DCIS) is designed to continue the work started in IBIS-I in determining whether a chemo preventive strategy towards breast cancer is beneficial. IBIS-I was set up to investigate the use of tamoxifen as a preventive agent for women with moderate to increased risk of getting breast cancer. IBIS-II (DCIS) is a randomized double blind control trial which will compare tamoxifen versus anastrozole in women with locally excised ER or PgR positive Ductal Carcinoma In-Situ (ER or PgR+ve DCIS).

| | |
|---|---------------------------------------|
| Actual start date of recruitment | 03 March 2003 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety, Efficacy, Scientific research |
| Long term follow-up duration | 5 Years |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | Sweden: 8 |
| Country: Number of subjects enrolled | United Kingdom: 889 |
| Country: Number of subjects enrolled | Italy: 323 |

| | |
|--------------------------------------|-----------------|
| Country: Number of subjects enrolled | Australia: 168 |
| Country: Number of subjects enrolled | Switzerland: 45 |
| Country: Number of subjects enrolled | Belgium: 104 |
| Country: Number of subjects enrolled | Chile: 17 |
| Country: Number of subjects enrolled | Finland: 7 |
| Country: Number of subjects enrolled | Ireland: 78 |
| Country: Number of subjects enrolled | France: 426 |
| Country: Number of subjects enrolled | Germany: 779 |
| Country: Number of subjects enrolled | Hungary: 15 |
| Country: Number of subjects enrolled | Malta: 4 |
| Country: Number of subjects enrolled | New Zealand: 10 |
| Country: Number of subjects enrolled | Turkey: 15 |
| Country: Number of subjects enrolled | Austria: 90 |
| Country: Number of subjects enrolled | India: 2 |
| Worldwide total number of subjects | 2980 |
| EEA total number of subjects | 1834 |

Notes:

Subjects enrolled per age group

| | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 2310 |
| From 65 to 84 years | 670 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Between March 3, 2003, and Feb 8, 2012, women who had been diagnosed with locally excised, hormone-receptor-positive DCIS were recruited from 236 centres in 17 countries (Sweden, UK, Italy, Australia, Switzerland, Belgium, Chile, Finland, Ireland, France, Germany, Hungary, Malta, New Zealand, Turkey, Austria, India).

Pre-assignment

Screening details:

Potentially eligible women were given an information sheet. Informed consent was taken from interested patients and pre-randomisation eligibility assessment was conducted. Eligibility criteria were clearly listed in the protocol.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

Arms

| | |
|------------------------------|-------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Anastrozole |

Arm description: -

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Anastrozole |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Anastrozole 1mg + Tamoxifen placebo. All treatment will be on a daily basis for 5 years and all women will take 2 tablets/day. One will contain tamoxifen or placebo. The second tablet will contain either anastrozole or placebo. Tablets will be supplied in numbered light-proof containers containing a 6-month supply. Each container will have extra tablets to allow for some delay in the next appointment.

| | |
|------------------|-----------|
| Arm title | Tamoxifen |
|------------------|-----------|

Arm description: -

| | |
|--|-------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Tamoxifen |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Tamoxifen 20mg + Anastrozole placebo. All treatment will be on a daily basis for 5 years and all women will take 2 tablets/day. One will contain tamoxifen or placebo. The second tablet will contain either anastrozole or placebo. Tablets will be supplied in numbered light-proof containers containing a 6-month supply. Each container will have extra tablets to allow for some delay in the next appointment.

| Number of subjects in period 1 | Anastrozole | Tamoxifen |
|---------------------------------------|-------------|-----------|
| Started | 1471 | 1509 |
| Completed | 1449 | 1489 |
| Not completed | 22 | 20 |
| Consent withdrawn by subject | 22 | 20 |

Baseline characteristics

Reporting groups

| | |
|--------------------------------|-------------|
| Reporting group title | Anastrozole |
| Reporting group description: - | |
| Reporting group title | Tamoxifen |
| Reporting group description: - | |

| Reporting group values | Anastrozole | Tamoxifen | Total |
|---|--------------|--------------|-------|
| Number of subjects | 1471 | 1509 | 2980 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 1139 | 1171 | 2310 |
| From 65-84 years | 332 | 338 | 670 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous Units: years | | | |
| median | 60.4 | 60.3 | |
| inter-quartile range (Q1-Q3) | 56.4 to 64.7 | 55.8 to 64.5 | - |
| Gender categorical Units: Subjects | | | |
| Female | 1471 | 1509 | 2980 |
| Male | 0 | 0 | 0 |

End points

End points reporting groups

| | |
|--------------------------------|-------------|
| Reporting group title | Anastrozole |
| Reporting group description: - | |
| Reporting group title | Tamoxifen |
| Reporting group description: - | |

Primary: Breast cancer recurrence, including recurrent DCIS and new contralateral tumours

| | |
|-----------------------------------|--|
| End point title | Breast cancer recurrence, including recurrent DCIS and new contralateral tumours |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| From 3 March 2003 to 31 May 2021. | |

| End point values | Anastrozole | Tamoxifen | | |
|---------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1449 | 1489 | | |
| Units: Breast cancer recurrence | 103 | 120 | | |

Statistical analyses

| | |
|---|-------------------------|
| Statistical analysis title | Univariate Cox Model |
| Comparison groups | Anastrozole v Tamoxifen |
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.33 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.88 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.67 |
| upper limit | 1.14 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.12 |

| | |
|--|-------------------------|
| Statistical analysis title | Multivariate Cox Model |
| Statistical analysis description: | |
| The following baseline characteristics will be included in the Cox proportional hazard models adjusting for baseline covariates for the incidence of breast cancer. The covariates will be included in the models regardless of statistical significance: • Hormone Replacement Therapy (HRT) use • Age • Body Mass Index (BMI) • Use of radiotherapy • Extent of margins • Grade (categorical: low, medium, high) | |
| Comparison groups | Anastrozole v Tamoxifen |
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.33 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.87 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.66 |
| upper limit | 1.15 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.12 |

Secondary: ER+ breast cancer recurrence, including recurrent DCIS and new contralateral tumours

| | |
|-----------------------------------|--|
| End point title | ER+ breast cancer recurrence, including recurrent DCIS and new contralateral tumours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| From 3 March 2003 to 31 May 2021. | |

| End point values | Anastrozole | Tamoxifen | | |
|-------------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1449 | 1489 | | |
| Units: ER+ breast cancer recurrence | 58 | 82 | | |

Statistical analyses

| | |
|---|-------------------------|
| Statistical analysis title | Univariate Cox Model |
| Comparison groups | Anastrozole v Tamoxifen |
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.06 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.72 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.52 |
| upper limit | 1.01 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.12 |

| | |
|--|-------------------------|
| Statistical analysis title | Multivariate Cox Model |
| Statistical analysis description: | |
| The following baseline characteristics will be included in the Cox proportional hazard models adjusting for baseline covariates for the incidence of ER+ breast cancer. The covariates will be included in the models regardless of statistical significance: • Hormone Replacement Therapy (HRT) use • Age • Body Mass Index (BMI) • Use of radiotherapy • Extent of margins • Grade (categorical: low, medium, high) | |
| Comparison groups | Anastrozole v Tamoxifen |
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.09 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.74 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.52 |
| upper limit | 1.05 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.13 |

Secondary: ER- breast cancer recurrence

| | |
|-----------------------------------|------------------------------|
| End point title | ER- breast cancer recurrence |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| From 3 March 2003 to 31 May 2021. | |

| End point values | Anastrozole | Tamoxifen | | |
|-------------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1449 | 1489 | | |
| Units: ER- breast cancer recurrence | 24 | 15 | | |

Statistical analyses

| Statistical analysis title | Univariate Cox Model |
|---|-------------------------|
| Comparison groups | Anastrozole v Tamoxifen |
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.13 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.64 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.86 |
| upper limit | 3.12 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.54 |

| Statistical analysis title | Multivariate Cox Model |
|--|-------------------------|
| Statistical analysis description: | |
| The following baseline characteristics will be included in the Cox proportional hazard models adjusting for baseline covariates for the incidence of ER- breast cancer. The covariates will be included in the models regardless of statistical significance: • Hormone Replacement Therapy (HRT) use • Age • Body Mass Index (BMI) • Use of radiotherapy • Extent of margins • Grade (categorical: low, medium, high) | |
| Comparison groups | Anastrozole v Tamoxifen |
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.26 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.46 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.75 |
| upper limit | 2.84 |

| | |
|----------------------|--------------------|
| Variability estimate | Standard deviation |
| Dispersion value | 0.5 |

Secondary: Breast cancer mortality

| | |
|-----------------------------------|-------------------------|
| End point title | Breast cancer mortality |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| From 3 March 2003 to 31 May 2021. | |

| End point values | Anastrozole | Tamoxifen | | |
|--------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1449 | 1489 | | |
| Units: Breast cancer mortality | 3 | 3 | | |

Statistical analyses

| | |
|---|-------------------------|
| Statistical analysis title | Univariate Cox Model |
| Comparison groups | Anastrozole v Tamoxifen |
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.97 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.03 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.21 |
| upper limit | 5.11 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.84 |

| | |
|--|-------------------------|
| Statistical analysis title | Multivariate Cox Model |
| Statistical analysis description: | |
| The following baseline characteristics will be included in the Cox proportional hazard models adjusting for baseline covariates for the incidence of breast cancer mortality. The covariates will be included in the models regardless of statistical significance: • Hormone Replacement Therapy (HRT) use • Age • Body Mass Index (BMI) • Use of radiotherapy • Extent of margins • Grade (categorical: low, medium, high) | |
| Comparison groups | Anastrozole v Tamoxifen |

| | |
|---|--------------------|
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.93 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.08 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.22 |
| upper limit | 5.36 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.88 |

Secondary: Non-breast cancer mortality

| | |
|-----------------------------------|-----------------------------|
| End point title | Non-breast cancer mortality |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| From 3 March 2003 to 31 May 2021. | |

| End point values | Anastrozole | Tamoxifen | | |
|------------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1449 | 1489 | | |
| Units: Non-breast cancer mortality | 59 | 65 | | |

Statistical analyses

| | |
|---|-------------------------|
| Statistical analysis title | Univariate Cox Model |
| Comparison groups | Tamoxifen v Anastrozole |
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.67 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.93 |

| | |
|----------------------|--------------------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.65 |
| upper limit | 1.32 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.17 |

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Multivariate Cox Model |
|-----------------------------------|------------------------|

Statistical analysis description:

The following baseline characteristics will be included in the Cox proportional hazard models adjusting for baseline covariates for the incidence of non-breast cancer mortality. The covariates will be included in the models regardless of statistical significance: • Hormone Replacement Therapy (HRT) use • Age • Body Mass Index (BMI) • Use of radiotherapy • Extent of margins • Grade (categorical: low, medium, high)

| | |
|---|-------------------------|
| Comparison groups | Anastrozole v Tamoxifen |
| Number of subjects included in analysis | 2938 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.38 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.85 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.59 |
| upper limit | 1.22 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.16 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From 3 March 2003 to 31 May 2021.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----|
| Dictionary version | 19 |
|--------------------|----|

Reporting groups

| | |
|-----------------------|-------------|
| Reporting group title | Anastrozole |
|-----------------------|-------------|

Reporting group description: -

| | |
|-----------------------|-----------|
| Reporting group title | Tamoxifen |
|-----------------------|-----------|

Reporting group description: -

| Serious adverse events | Anastrozole | Tamoxifen | |
|---|---------------------|---------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 333 / 1449 (22.98%) | 371 / 1489 (24.92%) | |
| number of deaths (all causes) | 62 | 69 | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Intraductal papilloma of breast | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast angiosarcoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast cancer in situ | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast cancer metastatic | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paget's disease of the breast | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Parathyroid tumour benign | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pituitary tumour benign | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thyroid adenoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carcinoid tumour of the caecum | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuroendocrine tumour | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Phaeochromocytoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thyroid cancer | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon adenoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Salivary gland adenoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenocarcinoma pancreas | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Anal cancer | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon cancer | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon cancer metastatic | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Colorectal cancer | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colorectal cancer metastatic | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Gastric cancer | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Gastrointestinal carcinoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal neoplasm | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Gastroesophageal cancer | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lip and/or oral cavity cancer | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Malignant palate neoplasm | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant peritoneal neoplasm | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal adenocarcinoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Oesophageal carcinoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Oral cavity cancer metastatic | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pancreatic carcinoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Pancreatic carcinoma metastatic | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Rectal cancer | | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Rectal cancer metastatic | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectosigmoid cancer recurrent | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Salivary gland cancer | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Essential thrombocythaemia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematological malignancy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Myeloproliferative disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Focal nodular hyperplasia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bile duct cancer | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Hepatic cancer | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic cancer metastatic | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Hepatocellular carcinoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute myeloid leukaemia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic lymphocytic leukaemia | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic myeloid leukaemia | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hairy cell leukaemia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-Hodgkin's lymphoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Mesothelioma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pleural mesothelioma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural mesothelioma malignant | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Metastases to bone | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to liver | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Metastases to lung | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Metastases to peritoneum | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to spine | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Adenoma benign | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign neoplasm | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemangioma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 4 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Malignant neoplasm of unknown primary site | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastatic neoplasm | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Metastatic squamous cell carcinoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neoplasm | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain neoplasm | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Meningeal neoplasm | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningioma | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intraocular melanoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple myeloma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Bladder cancer | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder transitional cell carcinoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cancer | | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Renal cell carcinoma | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transitional cell carcinoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign ovarian tumour | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ovarian adenoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine leiomyoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 6 / 1489 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 1 | 3 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine polyp | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cervix carcinoma recurrent | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial cancer | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 8 / 1489 (0.54%) | |
| occurrences causally related to treatment / all | 1 / 1 | 5 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Endometrial cancer metastatic | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Endometrial cancer stage I | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial neoplasm | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fallopian tube cancer | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ovarian cancer | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 7 / 1489 (0.47%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Bronchial carcinoma | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 3 | |
| Lung adenocarcinoma metastatic | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lung cancer metastatic | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 3 | |
| Lung neoplasm | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 8 / 1449 (0.55%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 4 | 0 / 0 | |
| Non-small cell lung cancer | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Small cell lung cancer recurrent | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Small cell lung cancer stage unspecified | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Tonsil cancer | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 5 / 1489 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant melanoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 5 / 1489 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Melanoma recurrent | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Metastatic malignant melanoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Angiomyolipoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Leiomyoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Inflammatory myofibroblastic tumour | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sarcoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sarcoma uterus | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Aortic dissection | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Arterial stenosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arteriosclerosis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Infarction | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Venous insufficiency | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypotension | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arterial thrombosis limb | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 14 / 1489 (0.94%) | |
| occurrences causally related to treatment / all | 3 / 5 | 8 / 14 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvic venous thrombosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombophlebitis superficial | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 1 | 2 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombosis | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 5 / 1489 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Venous thrombosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Venous thrombosis limb | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hot flush | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertension | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Phlebitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Varicose ulceration | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Varicose vein | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical and medical procedures | | | |
| Bunion operation | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hip arthroplasty | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 1449 (0.14%) | 5 / 1489 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint arthroplasty | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Knee arthroplasty | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rotator cuff repair | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mammoplasty | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic valve replacement | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cardiac pacemaker insertion | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve replacement | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thyroid operation | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thyroidectomy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye operation | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal hernia repair | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Appendicectomy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colectomy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hernia repair | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laparotomy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal prolapse repair | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystectomy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningioma surgery | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal laminectomy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal operation | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hysterectomy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oophorectomy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oophorectomy bilateral | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Salpingo-oophorectomy bilateral | | | |

| | | | |
|--|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine dilation and curettage | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine operation | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine tumour excision | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrectomy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Removal of inert matter from skin or subcutaneous tissue | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Scar excision | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin graft | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cancer surgery | | | |

| | | | |
|--|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Debridement | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Elective surgery | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lesion excision | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant tumour excision | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound closure | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery bypass | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac death | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Death | | | |
| subjects affected / exposed | 14 / 1449 (0.97%) | 10 / 1489 (0.67%) | |
| occurrences causally related to treatment / all | 0 / 14 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 14 | 0 / 10 | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest pain | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 6 / 1489 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Disease progression | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hernia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malaise | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multi-organ failure | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Pain | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polyp | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Swelling | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvic mass | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sudden cardiac death | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Immune system disorders | | | |
| Allergy to arthropod bite | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypersensitivity | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reproductive system and breast disorders | | | |
| Breast haematoma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast necrosis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast pain | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervical cyst | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervical dysplasia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervical polyp | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postmenopausal haemorrhage | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 6 / 1489 (0.40%) | |
| occurrences causally related to treatment / all | 1 / 1 | 4 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metrorrhagia | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ovarian atrophy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ovarian cyst | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Female genital tract fistula | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cystocele | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial dysplasia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial hyperplasia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 12 / 1489 (0.81%) | |
| occurrences causally related to treatment / all | 0 / 1 | 6 / 12 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial hypertrophy | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 5 / 1489 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectocele | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine atrophy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine polyp | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 15 / 1489 (1.01%) | |
| occurrences causally related to treatment / all | 1 / 1 | 9 / 15 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Uterine prolapse | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterovaginal prolapse | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vaginal prolapse | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vaginal disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vaginal haemorrhage | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 1449 (0.21%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vaginal polyp | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vulvovaginal discomfort | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute respiratory distress syndrome | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Pulmonary fibrosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pleural effusion | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 9 / 1489 (0.60%) | |
| occurrences causally related to treatment / all | 0 / 5 | 6 / 9 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cough | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemoptysis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Productive cough | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary mass | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory arrest | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Respiratory failure | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Sleep apnoea syndrome | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epistaxis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Nasal septum deviation | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tonsillar disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Panic attack | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Panic disorder | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Confusional state | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Depression | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hallucination | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Drug abuse | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sleep disorder | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Completed suicide | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Suicide attempt | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Ejection fraction decreased | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Heart rate increased | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigation | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood glucose fluctuation | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood glucose increased | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthroscopy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intraocular pressure increased | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Body temperature increased | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cystoscopy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hysteroscopy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Smear cervix abnormal | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Acetabulum fracture | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ankle fracture | | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 11 / 1489 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 10 | 2 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cartilage injury | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Facial bones fracture | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 1 / 3 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femur fracture | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fibula fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Foot fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Forearm fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fracture | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hand fracture | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hip fracture | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Humerus fracture | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint dislocation | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint sprain | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Limb injury | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower limb fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar vertebral fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meniscus lesion | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Patella fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvic fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Radius fracture | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 2 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rib fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sternal fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ulna fracture | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper limb fracture | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wrist fracture | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Radiation fibrosis - lung | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Radiation necrosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Radiation pneumonitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fall | | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Head injury | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Ligament injury | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ligament rupture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple injuries | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Road traffic accident | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Tendon rupture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Traumatic anuria | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intentional overdose | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple drug overdose | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dislocation of joint prosthesis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Incisional hernia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural haemorrhage | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural pulmonary embolism | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seroma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound decomposition | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial flutter | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Bradycardia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bundle branch block left | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bundle branch block right | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac arrest | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Extrasystoles | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tachycardia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Palpitations | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic valve incompetence | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute myocardial infarctioncardial | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Angina pectoris | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Angina unstable | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery disease | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery occlusion | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery stenosis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 6 / 1489 (0.40%) | |
| occurrences causally related to treatment / all | 1 / 4 | 2 / 6 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Cardiac failure | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cardiac failure congestive | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Left ventricular failure | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Nervous system disorders | | | |
| Arachnoiditis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Encephalitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain stem stroke | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery occlusion | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral infarction | | | |

| | | | |
|---|-------------------|------------------|--|
| subjects affected / exposed | 4 / 1449 (0.28%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Cerebral ischaemia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 2 / 10 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 1 / 10 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Trigeminal neuralgia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple sclerosis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Headache | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Migraine | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dementia Alzheimer's type | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paresis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Parkinson's disease | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tremor | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Altered state of consciousness | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic hyperosmolar coma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lethargy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Loss of consciousness | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Presyncope | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Autonomic nervous system imbalance | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Motor neurone disease | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic nephropathy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Guillain-Barre syndrome | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nerve compression | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervicobrachial syndrome | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sciatica | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ear and labyrinth disorders | | | |
| Deafness unilateral | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tinnitus | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertigo | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cataract cortical | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Glaucoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ocular hypertension | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Open angle glaucoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Optic ischaemic neuropathy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Keratitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular hole | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Papilloedema | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal detachment | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal tear | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal vein occlusion | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blindness unilateral | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vision blurred | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal hernia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterocoele | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hiatus hernia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colonic polyp | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gingival hypoplasia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulum intestinal | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatic disorder | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pancreatitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anal fistula | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric haemorrhage | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal haemorrhage | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematemesis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis ischaemic | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Crohn's disease | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastritis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroesophagitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ileitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Constipation | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Frequent bowel movements | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal discomfort | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nausea | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vomiting | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal obstruction | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Volvulus of small bowel | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric ulcer | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal ulcer | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peptic ulcer | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhoids | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Splenic artery aneurysm | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Varices oesophageal | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Biliary colic | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis chronic | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholelithiasis | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gallbladder polyp | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cirrhosis alcoholic | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Hepatic cirrhosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Hepatic cyst | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Urticaria | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pruritus | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rash | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Kidney enlargement | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal artery thrombosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cyst | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Renal failure acute | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Renal impairment | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urethral disorder | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematuria | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Incontinence | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mixed incontinence | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal colic | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stress urinary incontinence | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary retention | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocrine disorders | | | |
| Autoimmune thyroiditis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Goitre | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperthyroidism | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thyroiditis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Bone pain | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteopenia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteoporosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pain in jaw | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sjogren's syndrome | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fracture nonunion | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthralgia | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 5 / 1449 (0.35%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthritis | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteoarthritis | | | |
| subjects affected / exposed | 15 / 1449 (1.04%) | 11 / 1489 (0.74%) | |
| occurrences causally related to treatment / all | 3 / 15 | 2 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rheumatoid arthritis | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rhabdomyolysis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Trismus | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervical spinal stenosis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Foot deformity | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar spine flattening | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal column stenosis | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Back disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Back pain | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dupuytren's contracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Groin pain | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neck pain | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pain in extremity | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Synovitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tenosynovitis stenosaurs | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chondropathy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tenosynovitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Arthritis bacterial | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast cellulitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cellulitis | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia sepsis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumococcal sepsis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia pneumococcal | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Streptococcal sepsis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumocystis jirovecii pneumonia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Vulvovaginal candidiasis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal infection | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthritis infective | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast abscess | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 4 / 1489 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchiectasis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchopneumonia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulitis | | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 3 / 1489 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocarditis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infection | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Kidney infection | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Localised infection | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mastitis | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nail infection | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 10 / 1489 (0.67%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Postoperative wound infection | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory tract infection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Sialoadenitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Urosepsis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound infection | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Herpes ophthalmic | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Herpes zoster | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vestibular neuronitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viral infection | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic foot | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetes mellitus | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Folate deficiency | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Anastrozole | Tamoxifen | |
|---|-------------------------|-------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1323 / 1449 (91.30%) | 1380 / 1489 (92.68%) | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Benign breast neoplasm | | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 11 / 1489 (0.74%) | |
| occurrences (all) | 10 | 11 | |
| Breast cyst | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 4 | 2 | |
| Fibroadenoma of breast | | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 8 / 1489 (0.54%) | |
| occurrences (all) | 6 | 8 | |
| Breast cancer in situ | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 3 | 2 | |
| Breast cancer metastatic | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 1 | 1 | |
| Breast cancer recurrent | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 1 | 1 | |
| Skin papilloma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Adrenal adenoma | | | |

| | | |
|------------------------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Thyroid cyst | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Neuroendocrine carcinoma | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Anal polyp | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Colon adenoma | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gastric polyps | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Anal cancer | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Colon cancer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Colorectal cancer stage IV | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gastrointestinal cancer metastatic | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gastrointestinal carcinoma | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Intestinal adenocarcinoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Lip and/or oral cavity cancer | | |

| | | |
|-----------------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Oesophageal carcinoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Rectal cancer | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Focal nodular hyperplasia | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Hepatic cancer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Myelodysplastic syndrome | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Lymphoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Non-Hodgkin's lymphoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Mesothelioma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Metastases to bone | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Metastases to liver | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Metastases to lung | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Metastases to lymph nodes | | |

| | | |
|-------------------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Metastases to peritoneum | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Metastases to skin | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Metastasis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Adenoma benign | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Cholesteatoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Cyst | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Polyp | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) |
| occurrences (all) | 0 | 3 |
| Adenoid cystic carcinoma | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Angiosarcoma | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Carcinoma in situ | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Head and neck cancer | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Malignant neoplasm of unknown | | |

| | | |
|-----------------------------------|------------------|------------------|
| primary site | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Metastatic neoplasm | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Recurrent cancer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Squamous cell carcinoma | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) |
| occurrences (all) | 2 | 2 |
| Neuroma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Intracranial meningioma malignant | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Meningioma | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gammopathy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Renal cancer | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Genital cyst | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cervical polyp | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Degeneration of uterine fibroid | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | |
|-----------------------------|------------------|------------------|
| Ovarian cyst | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Uterine cyst | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Uterine leiomyoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 6 / 1489 (0.40%) |
| occurrences (all) | 0 | 6 |
| Uterine polyp | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Vaginal polyp | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Vulval polyp | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Endometrial cancer stage I | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Ovarian cancer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Uterine cancer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Vulval neoplasm | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Benign lung neoplasm | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Nasal polyps | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | |
|--|------------------|------------------|
| Adenosquamous cell lung cancer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Bronchial carcinoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Lung adenocarcinoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Lung carcinoma cell type unspecified recurrent | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Lung carcinoma cell type unspecified stage 0 | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Thymoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Tonsil cancer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Basal cell carcinoma | | |
| subjects affected / exposed | 8 / 1449 (0.55%) | 9 / 1489 (0.60%) |
| occurrences (all) | 8 | 9 |
| Bowen's disease | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Malignant melanoma | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 1 / 1489 (0.07%) |
| occurrences (all) | 4 | 1 |
| Malignant melanoma in situ | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Melanoma recurrent | | |

| | | | |
|---|-----------------------|-----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Skin cancer | | | |
| subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 4 / 1489 (0.27%) 4 | |
| Superficial spreading melanoma stage unspecified | | | |
| subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Lipoma | | | |
| subjects affected / exposed occurrences (all) | 3 / 1449 (0.21%) 3 | 1 / 1489 (0.07%) 1 | |
| Vascular disorders | | | |
| Accelerated hypertension | | | |
| subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Aneurysm | | | |
| subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Angina unstable | | | |
| subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Aortic stenosis | | | |
| subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 | |
| Carotid artery occlusion | | | |
| subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Carotid artery stenosis | | | |
| subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Cerebrovascular accident | | | |
| subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Circulatory collapse | | | |

| | | |
|-----------------------------|------------------------|------------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Coronary artery disease | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Deep vein thrombosis | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 3 / 1489 (0.20%) |
| occurrences (all) | 5 | 3 |
| Dizziness | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Embolism | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 5 / 1489 (0.34%) |
| occurrences (all) | 2 | 5 |
| Epistaxis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Essential hypertension | | |
| subjects affected / exposed | 68 / 1449 (4.69%) | 54 / 1489 (3.63%) |
| occurrences (all) | 68 | 54 |
| Femoral artery aneurysm | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Haematoma | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 8 / 1489 (0.54%) |
| occurrences (all) | 4 | 8 |
| Haemorrhage intracranial | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Hot flush | | |
| subjects affected / exposed | 161 / 1449 (11.11%) | 184 / 1489 (12.36%) |
| occurrences (all) | 161 | 184 |
| Hypertension | | |
| subjects affected / exposed | 28 / 1449 (1.93%) | 22 / 1489 (1.48%) |
| occurrences (all) | 28 | 22 |

| | | |
|------------------------------|------------------|------------------|
| Hypotension | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) |
| occurrences (all) | 2 | 3 |
| Ischaemia | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Ischaemic stroke | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Lymphoedema | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 8 / 1489 (0.54%) |
| occurrences (all) | 4 | 8 |
| Malignant hypertension | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Orthostatic hypotension | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Peripheral coldness | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Peripheral vascular disorder | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Phlebitis | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 7 / 1489 (0.47%) |
| occurrences (all) | 3 | 7 |
| Postmenopausal haemorrhage | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Presyncope | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Pulmonary embolism | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) |
| occurrences (all) | 3 | 2 |

| | | | |
|---------------------------------|------------------|------------------|--|
| Spider vein | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Syncope | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 1 | 2 | |
| Temporal arteritis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Thrombophlebitis superficial | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 6 / 1489 (0.40%) | |
| occurrences (all) | 1 | 6 | |
| Thrombosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 7 | 2 | |
| Varicose ulceration | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Varicose vein | | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 9 / 1489 (0.60%) | |
| occurrences (all) | 7 | 9 | |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Venous insufficiency | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Surgical and medical procedures | | | |
| Abscess drainage | | | |

| | | |
|-----------------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Acupuncture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Adrenal gland operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Anal polypectomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Angioplasty | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) |
| occurrences (all) | 2 | 2 |
| Ankle operation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Aortic valve replacement | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Appendicectomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Arterial stent insertion | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Arthroscopic surgery | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Bladder operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Bone lesion excision | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Bone operation | | |

| | | |
|-----------------------------------|-------------------|------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Breast cyst drainage | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Breast lump removal | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Breast reconstruction | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Bunion operation | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 8 / 1489 (0.54%) |
| occurrences (all) | 6 | 8 |
| Cancer surgery | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Cardiac ablation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Cardiac operation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cardiac pacemaker insertion | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cardiac resynchronisation therapy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cardioversion | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Carpal tunnel decompression | | |
| subjects affected / exposed | 13 / 1449 (0.90%) | 3 / 1489 (0.20%) |
| occurrences (all) | 13 | 3 |
| Cataract operation | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 18 / 1449 (1.24%) | 26 / 1489 (1.75%) |
| occurrences (all) | 18 | 26 |
| Cervical polypectomy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Chemotherapy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Chiropractic | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cholecystectomy | | |
| subjects affected / exposed | 9 / 1449 (0.62%) | 7 / 1489 (0.47%) |
| occurrences (all) | 9 | 7 |
| Colon operation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Colon polypectomy | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 6 / 1489 (0.40%) |
| occurrences (all) | 3 | 6 |
| Colonoscopy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 4 / 1489 (0.27%) |
| occurrences (all) | 1 | 4 |
| Colostomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Colporrhaphy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Coronary artery bypass | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Cyst removal | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Debridement | | |

| | | |
|-----------------------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dental care | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dental implantation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Dupuytren's contracture operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Ear operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Elbow operation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Elective surgery | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Emergency care | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Endocervical curettage | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Ethmoid sinus surgery | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Eye operation | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Foot operation | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) |
| occurrences (all) | 2 | 2 |
| Gallbladder operation | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Haemorrhoid operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Hand repair operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Heart valve replacement | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Hernia repair | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| High frequency ablation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hip arthroplasty | | |
| subjects affected / exposed | 14 / 1449 (0.97%) | 10 / 1489 (0.67%) |
| occurrences (all) | 14 | 10 |
| Hip surgery | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 4 / 1489 (0.27%) |
| occurrences (all) | 6 | 4 |
| Hospitalisation | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Hysterectomy | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 17 / 1489 (1.14%) |
| occurrences (all) | 4 | 17 |
| Ileostomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Incisional hernia repair | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Inguinal hernia repair | | |

| | | |
|------------------------------------|-------------------|-------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Intervertebral disc operation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Intestinal resection | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Intraocular lens implant | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Intra-uterine contraceptive device | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Jaw operation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Joint manipulation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Joint surgery | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Knee arthroplasty | | |
| subjects affected / exposed | 12 / 1449 (0.83%) | 13 / 1489 (0.87%) |
| occurrences (all) | 12 | 13 |
| Knee operation | | |
| subjects affected / exposed | 8 / 1449 (0.55%) | 3 / 1489 (0.20%) |
| occurrences (all) | 8 | 3 |
| Large intestine operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Laryngeal polypectomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Lesion excision | | |

| | | |
|-----------------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Limb operation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Lipoma excision | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 7 / 1489 (0.47%) |
| occurrences (all) | 0 | 7 |
| Local anaesthesia | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Lung lobectomy | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Lymphadenectomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Mammoplasty | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 4 / 1489 (0.27%) |
| occurrences (all) | 3 | 4 |
| Mastectomy | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 4 / 1489 (0.27%) |
| occurrences (all) | 2 | 4 |
| Meningioma surgery | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Meniscus removal | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) |
| occurrences (all) | 2 | 3 |
| Mitral valve replacement | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Mole excision | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Muscle operation | | |

| | | |
|-----------------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Nail operation | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Nasal operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Nephrectomy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Nerve block | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Oophorectomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) |
| occurrences (all) | 0 | 3 |
| Oophorectomy bilateral | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 5 / 1489 (0.34%) |
| occurrences (all) | 2 | 5 |
| Open reduction of fracture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Ovarian cystectomy | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) |
| occurrences (all) | 3 | 1 |
| Parathyroidectomy | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Pelvic floor repair | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 4 / 1489 (0.27%) |
| occurrences (all) | 1 | 4 |
| Physiotherapy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Plastic surgery | | |

| | | |
|---------------------------------|------------------|-------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Polypectomy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 12 / 1489 (0.81%) |
| occurrences (all) | 1 | 12 |
| Prolapse repair | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Prosthesis implantation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Radical mastectomy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Radiotherapy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Renal cyst excision | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Retinal laser coagulation | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Retinal operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Salpingectomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Salpingo-oophorectomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Salpingo-oophorectomy bilateral | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Sclerotherapy | | |

| | | |
|-----------------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Shoulder arthroplasty | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Shoulder operation | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 3 / 1489 (0.20%) |
| occurrences (all) | 6 | 3 |
| Simple mastectomy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Sinus operation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Skin graft | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Skin lesion excision | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 3 / 1489 (0.20%) |
| occurrences (all) | 5 | 3 |
| Skin neoplasm excision | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 4 / 1489 (0.27%) |
| occurrences (all) | 2 | 4 |
| Spinal decompression | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Spinal laminectomy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Spinal operation | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) |
| occurrences (all) | 2 | 2 |
| Stent placement | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Steroid therapy | | |

| | | |
|-------------------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Surgery | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 4 / 1489 (0.27%) |
| occurrences (all) | 4 | 4 |
| Tendon operation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Tendon sheath lesion excision | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Therapeutic skin care topical | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Thoracotomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Thyroid operation | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) |
| occurrences (all) | 3 | 1 |
| Thyroidectomy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Toe amputation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Toe operation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Tooth extraction | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 6 / 1489 (0.40%) |
| occurrences (all) | 2 | 6 |
| Trabeculectomy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Transfusion | | |

| | | | |
|--------------------------------------|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Tumour excision | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Umbilical hernia repair | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Uterine cervix dilation procedure | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Uterine cystectomy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Uterine dilation and curettage | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 4 / 1489 (0.27%) | |
| occurrences (all) | 3 | 4 | |
| Uterine polypectomy | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Uterine prolapse repair | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Varicose vein operation | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Venous ligation | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 1 | 2 | |
| Venous operation | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Vocal cordectomy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| General disorders and administration | | | |

| | | | |
|-----------------------------|-------------------|-------------------|--|
| site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 6 / 1489 (0.40%) | |
| occurrences (all) | 3 | 6 | |
| Asthenia | | | |
| subjects affected / exposed | 23 / 1449 (1.59%) | 25 / 1489 (1.68%) | |
| occurrences (all) | 23 | 25 | |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Chest pain | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 6 / 1489 (0.40%) | |
| occurrences (all) | 4 | 6 | |
| Chills | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Disease recurrence | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Facial pain | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Fatigue | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 1 | 2 | |
| Gait disturbance | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Hernia | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 2 | 2 | |
| Hot flush | | | |

| | | |
|-----------------------------|---------------------|---------------------|
| subjects affected / exposed | 19 / 1449 (1.31%) | 14 / 1489 (0.94%) |
| occurrences (all) | 19 | 14 |
| Inflammation | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Influenza like illness | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Irritability | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 1 / 1489 (0.07%) |
| occurrences (all) | 6 | 1 |
| Lethargy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Malaise | | |
| subjects affected / exposed | 165 / 1449 (11.39%) | 177 / 1489 (11.89%) |
| occurrences (all) | 165 | 177 |
| Night sweats | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 3 / 1489 (0.20%) |
| occurrences (all) | 5 | 3 |
| Oedema | | |
| subjects affected / exposed | 21 / 1449 (1.45%) | 28 / 1489 (1.88%) |
| occurrences (all) | 21 | 28 |
| Oedema peripheral | | |
| subjects affected / exposed | 18 / 1449 (1.24%) | 9 / 1489 (0.60%) |
| occurrences (all) | 18 | 9 |
| Pain | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Polyp | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 6 / 1489 (0.40%) |
| occurrences (all) | 2 | 6 |
| Thirst | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |

| | | | |
|---|-----------------------|-------------------------|--|
| Adverse drug reaction subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Adverse reaction subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 0 / 1489 (0.00%) 0 | |
| Cyst subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 2 / 1489 (0.13%) 2 | |
| Dysplasia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Fat necrosis subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 1 / 1489 (0.07%) 1 | |
| Fibrosis subjects affected / exposed occurrences (all) | 6 / 1449 (0.41%) 6 | 3 / 1489 (0.20%) 3 | |
| Hyperplasia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Immune system disorders | | | |
| Asthma subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 0 / 1489 (0.00%) 0 | |
| Drug hypersensitivity subjects affected / exposed occurrences (all) | 5 / 1449 (0.35%) 5 | 0 / 1489 (0.00%) 0 | |
| Hypersensitivity subjects affected / exposed occurrences (all) | 3 / 1449 (0.21%) 3 | 10 / 1489 (0.67%) 10 | |
| Multiple allergies subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Antiphospholipid syndrome | | | |

| | | | |
|---|-----------------------|-----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Polymyalgia rheumatica subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 | |
| Rheumatoid arthritis subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Polyarteritis nodosa subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Temporal arteritis subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Social circumstances Bereavement subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Ex-tobacco user subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Reproductive system and breast disorders Adnexa uteri pain subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 3 / 1489 (0.20%) 3 | |
| Arthritis climacteric subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Benign breast neoplasm subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Breast abscess subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Breast calcifications | | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 4 / 1449 (0.28%) | 4 / 1489 (0.27%) |
| occurrences (all) | 4 | 4 |
| Breast cancer in situ | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Breast cancer metastatic | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Breast cancer recurrent | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Breast cyst | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 7 / 1489 (0.47%) |
| occurrences (all) | 10 | 7 |
| Breast discharge | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 5 / 1489 (0.34%) |
| occurrences (all) | 6 | 5 |
| Breast discomfort | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Breast disorder | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 18 / 1489 (1.21%) |
| occurrences (all) | 7 | 18 |
| Breast hyperplasia | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Breast infection | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Breast necrosis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Breast pain | | |
| subjects affected / exposed | 70 / 1449 (4.83%) | 66 / 1489 (4.43%) |
| occurrences (all) | 70 | 66 |
| Breast swelling | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cervical dysplasia | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Cervical polyp | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 11 / 1489 (0.74%) |
| occurrences (all) | 2 | 11 |
| Cystocele | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Dysmenorrhoea | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dyspareunia | | |
| subjects affected / exposed | 11 / 1449 (0.76%) | 11 / 1489 (0.74%) |
| occurrences (all) | 11 | 11 |
| Endometrial disorder | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Endometrial hyperplasia | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 18 / 1489 (1.21%) |
| occurrences (all) | 0 | 18 |
| Endometrial hypertrophy | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 34 / 1489 (2.28%) |
| occurrences (all) | 2 | 34 |
| Endometriosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Fibrocystic breast disease | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 8 / 1489 (0.54%) |
| occurrences (all) | 4 | 8 |
| Galactorrhoea | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Gynaecomastia | | |

| | | |
|---------------------------------|---------------------|---------------------|
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Hot flush | | |
| subjects affected / exposed | 815 / 1449 (56.25%) | 898 / 1489 (60.31%) |
| occurrences (all) | 815 | 898 |
| Intraductal papilloma of breast | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Mastitis | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Menopausal symptoms | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Menorrhagia | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Metrorrhagia | | |
| subjects affected / exposed | 13 / 1449 (0.90%) | 20 / 1489 (1.34%) |
| occurrences (all) | 13 | 20 |
| Night sweats | | |
| subjects affected / exposed | 70 / 1449 (4.83%) | 74 / 1489 (4.97%) |
| occurrences (all) | 70 | 74 |
| Nipple disorder | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Nipple pain | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Ovarian cyst | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 9 / 1489 (0.60%) |
| occurrences (all) | 10 | 9 |
| Ovarian mass | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | |
|-----------------------------|-------------------|-------------------|
| Pelvic pain | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Perineal pain | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Postmenopausal haemorrhage | | |
| subjects affected / exposed | 13 / 1449 (0.90%) | 12 / 1489 (0.81%) |
| occurrences (all) | 13 | 12 |
| Premenstrual syndrome | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Sexual dysfunction | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Uterine atrophy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Uterine cyst | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Uterine fibrosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Uterine haemorrhage | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Uterine leiomyoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Uterine polyp | | |
| subjects affected / exposed | 9 / 1449 (0.62%) | 25 / 1489 (1.68%) |
| occurrences (all) | 9 | 25 |
| Uterine prolapse | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | |
|-----------------------------|-------------------|--------------------|
| Uterine spasm | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Vaginal cyst | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Vaginal discharge | | |
| subjects affected / exposed | 31 / 1449 (2.14%) | 140 / 1489 (9.40%) |
| occurrences (all) | 31 | 140 |
| Vaginal disorder | | |
| subjects affected / exposed | 20 / 1449 (1.38%) | 22 / 1489 (1.48%) |
| occurrences (all) | 20 | 22 |
| Vaginal haemorrhage | | |
| subjects affected / exposed | 32 / 1449 (2.21%) | 78 / 1489 (5.24%) |
| occurrences (all) | 32 | 78 |
| Vaginal inflammation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Vaginal polyp | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Vaginal prolapse | | |
| subjects affected / exposed | 8 / 1449 (0.55%) | 11 / 1489 (0.74%) |
| occurrences (all) | 8 | 11 |
| Vaginal swelling | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Vulval abscess | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Vulval neoplasm | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Vulval polyp | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | | |
|---|-------------------------------|-------------------------------|--|
| Vulvovaginal dryness subjects affected / exposed occurrences (all) | 201 / 1449 (13.87%) 201 | 166 / 1489 (11.15%) 166 | |
| Vulvovaginal pain subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Vulvovaginal pruritus subjects affected / exposed occurrences (all) | 19 / 1449 (1.31%) 19 | 47 / 1489 (3.16%) 47 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma subjects affected / exposed occurrences (all) | 10 / 1449 (0.69%) 10 | 12 / 1489 (0.81%) 12 | |
| Bronchitis chronic subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 2 / 1489 (0.13%) 2 | |
| Chest discomfort subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Chest pain subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all) | 4 / 1449 (0.28%) 4 | 6 / 1489 (0.40%) 6 | |
| Cough subjects affected / exposed occurrences (all) | 16 / 1449 (1.10%) 16 | 24 / 1489 (1.61%) 24 | |
| Dry throat subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Dyspnoea subjects affected / exposed occurrences (all) | 21 / 1449 (1.45%) 21 | 30 / 1489 (2.01%) 30 | |
| Dyspnoea exertional | | | |

| | | |
|--|-------------------|-------------------|
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Emphysema | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Epistaxis | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 3 / 1489 (0.20%) |
| occurrences (all) | 5 | 3 |
| Haemoptysis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Increased upper airway secretion | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Lobar pneumonia | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Lower respiratory tract infection | | |
| subjects affected / exposed | 22 / 1449 (1.52%) | 53 / 1489 (3.56%) |
| occurrences (all) | 22 | 53 |
| Lung cancer metastatic | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Lung disorder | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Multifocal micronodular pneumocyte hyperplasia | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Nasal congestion | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Nasal discomfort | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |

| | | |
|---------------------------------|------------------|------------------|
| Nasal dryness | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Nasal polyps | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Pertussis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Pleurisy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Pleuritic pain | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Pneumonia | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 3 / 1489 (0.20%) |
| occurrences (all) | 7 | 3 |
| Pulmonary arterial hypertension | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 4 / 1489 (0.27%) |
| occurrences (all) | 4 | 4 |
| Pulmonary embolism | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Pulmonary hypertension | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Respiratory disorder | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 4 / 1489 (0.27%) |
| occurrences (all) | 2 | 4 |
| Respiratory distress | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rhinitis allergic | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 5 / 1489 (0.34%) |
| occurrences (all) | 2 | 5 |

| | | | |
|-----------------------------------|-------------------|-------------------|--|
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Sleep apnoea syndrome | | | |
| subjects affected / exposed | 24 / 1449 (1.66%) | 25 / 1489 (1.68%) | |
| occurrences (all) | 24 | 25 | |
| Throat tightness | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 1 | 2 | |
| Tonsillar disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 7 / 1489 (0.47%) | |
| occurrences (all) | 4 | 7 | |
| Psychiatric disorders | | | |
| Agitation | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Amnesia | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Aggression | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Alcohol problem | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Anxiety | | | |

| | | |
|-----------------------------|--------------------|-------------------|
| subjects affected / exposed | 15 / 1449 (1.04%) | 22 / 1489 (1.48%) |
| occurrences (all) | 15 | 22 |
| Bipolar I disorder | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Cognitive disorder | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Depression | | |
| subjects affected / exposed | 67 / 1449 (4.62%) | 70 / 1489 (4.70%) |
| occurrences (all) | 67 | 70 |
| Eating disorder | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Emotional disorder | | |
| subjects affected / exposed | 27 / 1449 (1.86%) | 36 / 1489 (2.42%) |
| occurrences (all) | 27 | 36 |
| Hallucination | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Insomnia | | |
| subjects affected / exposed | 109 / 1449 (7.52%) | 93 / 1489 (6.25%) |
| occurrences (all) | 109 | 93 |
| Loss of libido | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 12 / 1489 (0.81%) |
| occurrences (all) | 10 | 12 |
| Mental disorder | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) |
| occurrences (all) | 2 | 3 |
| Nervousness | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) |
| occurrences (all) | 3 | 2 |
| Neurosis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 5 / 1489 (0.34%) |
| occurrences (all) | 0 | 5 |
| Nightmare | | |

| | | | |
|--|-----------------------|-----------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 2 / 1489 (0.13%) 2 | |
| Personality disorder subjects affected / exposed occurrences (all) | 3 / 1449 (0.21%) 3 | 0 / 1489 (0.00%) 0 | |
| Phobia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Restlessness subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 3 / 1489 (0.20%) 3 | |
| Sleep disorder subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Somnolence subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Stress subjects affected / exposed occurrences (all) | 4 / 1449 (0.28%) 4 | 5 / 1489 (0.34%) 5 | |
| Suicidal ideation subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Hepatobiliary disorders Cholecystitis subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Cholecystitis acute subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Cholecystitis chronic subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Cholelithiasis subjects affected / exposed occurrences (all) | 4 / 1449 (0.28%) 4 | 8 / 1489 (0.54%) 8 | |

| | | | |
|---|-----------------------|-----------------------|--|
| Gallbladder disorder subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Haemochromatosis subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 2 / 1489 (0.13%) 2 | |
| Hepatic cirrhosis subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Hepatitis subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 3 / 1489 (0.20%) 3 | |
| Liver disorder subjects affected / exposed occurrences (all) | 3 / 1449 (0.21%) 3 | 3 / 1489 (0.20%) 3 | |
| Hepatobiliary carcinoma in situ subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Investigations | | | |
| Biopsy lymph gland subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 | |
| Angiogram subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Arteriogram coronary subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 | |
| Blood pressure subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 2 / 1489 (0.13%) 2 | |
| Blood pressure abnormal subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Blood pressure increased | | | |

| | | |
|---|------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cardiac murmur | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cardiovascular evaluation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Catheterisation cardiac | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Echocardiogram | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Electrocardiogram | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) |
| occurrences (all) | 3 | 2 |
| Electrocardiogram abnormal | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Electrocardiogram ST segment depression | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Heart rate decreased | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Heart rate irregular | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Scan myocardial perfusion | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Ultrasound Doppler | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |

| | | |
|--|------------------|------------------|
| Venogram | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Gene mutation identification test positive | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Biopsy thyroid gland | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Thyroid function test abnormal | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Barium enema | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Barium swallow | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Biopsy colon abnormal | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Biopsy oesophagus | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Colonoscopy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 5 / 1489 (0.34%) |
| occurrences (all) | 0 | 5 |
| Endoscopy upper gastrointestinal tract | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 5 / 1489 (0.34%) |
| occurrences (all) | 2 | 5 |
| Oesophagogastrectomy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Sigmoidoscopy | | |

| | | |
|-------------------------------------|-------------------|-------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Ultrasound abdomen | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| White blood cell count decreased | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Red blood cell count | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Biopsy liver | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gamma-glutamyltransferase increased | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Hepatic enzyme increased | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Liver function test abnormal | | |
| subjects affected / exposed | 17 / 1449 (1.17%) | 21 / 1489 (1.41%) |
| occurrences (all) | 17 | 21 |
| Ultrasound biliary tract | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Biopsy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Computerised tomogram | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Endoscopy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |

| | | |
|---------------------------------------|-------------------|-------------------|
| Imaging procedure | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Investigation | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Needle biopsy site unspecified normal | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Nuclear magnetic resonance imaging | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 2 / 1489 (0.13%) |
| occurrences (all) | 4 | 2 |
| X-ray | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 2 / 1489 (0.13%) |
| occurrences (all) | 4 | 2 |
| Free fatty acids increased | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Glucose tolerance test | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 3 / 1489 (0.20%) |
| occurrences (all) | 5 | 3 |
| Arthroscopy | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 7 / 1489 (0.47%) |
| occurrences (all) | 6 | 7 |
| Bone densitometry | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 3 / 1489 (0.20%) |
| occurrences (all) | 4 | 3 |
| Bone density decreased | | |
| subjects affected / exposed | 56 / 1449 (3.86%) | 42 / 1489 (2.82%) |
| occurrences (all) | 56 | 42 |
| Acoustic stimulation tests | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Brain scan normal | | |

| | | |
|------------------------------|--------------------|--------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Scan brain | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Body height decreased | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Body temperature increased | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 1 / 1489 (0.07%) |
| occurrences (all) | 4 | 1 |
| Gastrointestinal examination | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Gynaecological examination | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Neurological examination | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Ophthalmological examination | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 4 / 1489 (0.27%) |
| occurrences (all) | 4 | 4 |
| Orthopaedic examination | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Weight decreased | | |
| subjects affected / exposed | 23 / 1449 (1.59%) | 15 / 1489 (1.01%) |
| occurrences (all) | 23 | 15 |
| Weight increased | | |
| subjects affected / exposed | 126 / 1449 (8.70%) | 133 / 1489 (8.93%) |
| occurrences (all) | 126 | 133 |
| Cystoscopy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Ultrasound kidney | | |

| | | |
|-----------------------------|------------------|-------------------|
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Aspiration breast | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Biopsy breast | | |
| subjects affected / exposed | 8 / 1449 (0.55%) | 12 / 1489 (0.81%) |
| occurrences (all) | 8 | 12 |
| Biopsy breast normal | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Biopsy cervix | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Biopsy endometrium | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 7 / 1489 (0.47%) |
| occurrences (all) | 2 | 7 |
| Biopsy endometrium normal | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Biopsy testes normal | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Biopsy uterus | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) |
| occurrences (all) | 0 | 3 |
| Biopsy vagina | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Hysteroscopy | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 16 / 1489 (1.07%) |
| occurrences (all) | 4 | 16 |
| Mammogram | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Mammogram abnormal | | |

| | | |
|------------------------------|------------------|-------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Mammogram normal | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Smear cervix | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Smear cervix abnormal | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 6 / 1489 (0.40%) |
| occurrences (all) | 1 | 6 |
| Ultrasound breast | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 10 / 1489 (0.67%) |
| occurrences (all) | 2 | 10 |
| Ultrasound pelvis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Ultrasound scan vagina | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 4 / 1489 (0.27%) |
| occurrences (all) | 0 | 4 |
| Ultrasound uterus | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Chest X-ray | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Computerised tomogram thorax | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Laryngoscopy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Sclerotherapy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Serum ferritin increased | | |

| | | | |
|--|------------------|-------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 9 / 1449 (0.62%) | 10 / 1489 (0.67%) | |
| occurrences (all) | 9 | 10 | |
| Bone fragmentation | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Bursa injury | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Cartilage injury | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 1 | 1 | |
| Cervical vertebral fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Clavicle fracture | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 4 / 1489 (0.27%) | |
| occurrences (all) | 0 | 4 | |
| Facial bones fracture | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Femur fracture | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Fibula fracture | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Foot fracture | | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 14 / 1449 (0.97%) | 17 / 1489 (1.14%) |
| occurrences (all) | 14 | 17 |
| Forearm fracture | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) |
| occurrences (all) | 3 | 1 |
| Fracture | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 5 / 1489 (0.34%) |
| occurrences (all) | 5 | 5 |
| Fracture displacement | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Fractured coccyx | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Fractured sacrum | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Haemarthrosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hand fracture | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 7 / 1489 (0.47%) |
| occurrences (all) | 7 | 7 |
| Hip fracture | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Humerus fracture | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 1 / 1489 (0.07%) |
| occurrences (all) | 6 | 1 |
| Joint dislocation | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 6 / 1489 (0.40%) |
| occurrences (all) | 5 | 6 |
| Lower limb fracture | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 4 / 1489 (0.27%) |
| occurrences (all) | 3 | 4 |
| Meniscus injury | | |

| | | |
|-----------------------------|-------------------|------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Meniscus lesion | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Multiple fractures | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Patella fracture | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Pelvic fracture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Radius fracture | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 2 / 1489 (0.13%) |
| occurrences (all) | 6 | 2 |
| Rib fracture | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 6 / 1489 (0.40%) |
| occurrences (all) | 7 | 6 |
| Skull fracture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Spinal fracture | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 7 / 1489 (0.47%) |
| occurrences (all) | 5 | 7 |
| Traumatic fracture | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) |
| occurrences (all) | 2 | 2 |
| Ulna fracture | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Upper limb fracture | | |
| subjects affected / exposed | 18 / 1449 (1.24%) | 7 / 1489 (0.47%) |
| occurrences (all) | 18 | 7 |
| Wrist fracture | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 30 / 1449 (2.07%) | 15 / 1489 (1.01%) |
| occurrences (all) | 30 | 15 |
| Food poisoning | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 7 / 1489 (0.47%) |
| occurrences (all) | 6 | 7 |
| Animal bite | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Corneal abrasion | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Excoriation | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 9 / 1489 (0.60%) |
| occurrences (all) | 10 | 9 |
| Fall | | |
| subjects affected / exposed | 19 / 1449 (1.31%) | 16 / 1489 (1.07%) |
| occurrences (all) | 19 | 16 |
| Injury | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Ligament injury | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Ligament rupture | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Mouth injury | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) |
| occurrences (all) | 2 | 2 |
| Muscle rupture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Perineal laceration | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Retinal detachment | | |

| | | |
|------------------------------------|-------------------|-------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Road traffic accident | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) |
| occurrences (all) | 3 | 1 |
| Soft tissue injury | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 13 / 1489 (0.87%) |
| occurrences (all) | 10 | 13 |
| Superficial injury of eye | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Tendon rupture | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 1 / 1489 (0.07%) |
| occurrences (all) | 4 | 1 |
| Tooth injury | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Vascular injury | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Vena cava injury | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Vitreous detachment | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Deep vein thrombosis postoperative | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Device intolerance | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Implant tissue necrosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Post procedural complication | | |

| | | | |
|--|-----------------------|-------------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Post procedural haemorrhage subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 | |
| Postoperative thrombosis subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Postoperative wound complication subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Procedural pain subjects affected / exposed occurrences (all) | 3 / 1449 (0.21%) 3 | 11 / 1489 (0.74%) 11 | |
| Seroma subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 | |
| Vascular graft occlusion subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Congenital, familial and genetic disorders | | | |
| Gastrointestinal angiodysplasia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Heart disease congenital subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Cataract congenital subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Haemangioma of retina subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Osteoporosis | | | |

| | | | |
|--|-----------------------|-----------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Congenital cystic kidney disease subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 0 / 1489 (0.00%) 0 | |
| Basal cell naevus syndrome subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Keratosis follicular subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Cardiac disorders | | | |
| Arrhythmia subjects affected / exposed occurrences (all) | 5 / 1449 (0.35%) 5 | 7 / 1489 (0.47%) 7 | |
| Atrial fibrillation subjects affected / exposed occurrences (all) | 5 / 1449 (0.35%) 5 | 7 / 1489 (0.47%) 7 | |
| Atrial flutter subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Atrial tachycardia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Bradyarrhythmia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Tachycardia subjects affected / exposed occurrences (all) | 9 / 1449 (0.62%) 9 | 9 / 1489 (0.60%) 9 | |
| Cardiac discomfort subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Cardiac disorder subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 1 / 1489 (0.07%) 1 | |

| | | |
|-----------------------------|-------------------|-------------------|
| Cardiovascular disorder | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Dizziness | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dyspnoea | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Palpitations | | |
| subjects affected / exposed | 19 / 1449 (1.31%) | 18 / 1489 (1.21%) |
| occurrences (all) | 19 | 18 |
| Aortic valve incompetence | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Aortic valve stenosis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Mitral valve incompetence | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Mitral valve prolapse | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Angina pectoris | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 0 / 1489 (0.00%) |
| occurrences (all) | 6 | 0 |
| Angina unstable | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Chest pain | | |
| subjects affected / exposed | 14 / 1449 (0.97%) | 15 / 1489 (1.01%) |
| occurrences (all) | 14 | 15 |
| Coronary artery disease | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |

| | | |
|-----------------------------|------------------|------------------|
| Coronary artery stenosis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Myocardial infarction | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Myocardial ischaemia | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Endocarditis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cardiac failure | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cardiac failure chronic | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Left ventricular failure | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Cardiomegaly | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 6 / 1489 (0.40%) |
| occurrences (all) | 2 | 6 |
| Cardiomyopathy | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Ventricular dysfunction | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Dressler's syndrome | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Pericardial effusion | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |

| | | | |
|-----------------------------|------------------|------------------|--|
| Nervous system disorders | | | |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Cerebral vasoconstriction | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 2 | 1 | |
| Haemorrhagic stroke | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Temporal arteritis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 3 | 1 | |
| Anosmia | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Cranial nerve paralysis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Facial palsy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) | |
| occurrences (all) | 1 | 3 | |
| Facial spasm | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Neuritis cranial | | | |

| | | |
|--|-------------------|-------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Optic neuritis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Vith nerve paralysis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Multiple sclerosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 4 / 1489 (0.27%) |
| occurrences (all) | 1 | 4 |
| Headache | | |
| subjects affected / exposed | 82 / 1449 (5.66%) | 61 / 1489 (4.10%) |
| occurrences (all) | 82 | 61 |
| Migraine | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 10 / 1489 (0.67%) |
| occurrences (all) | 10 | 10 |
| Migraine with aura | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Tension headache | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Amnesia | | |
| subjects affected / exposed | 27 / 1449 (1.86%) | 28 / 1489 (1.88%) |
| occurrences (all) | 27 | 28 |
| Cognitive disorder | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Dementia Alzheimer's type | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dementia of the Alzheimer's type, with depressed mood | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |

| | | |
|--|-------------------------|-------------------------|
| Disturbance in attention subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 4 / 1489 (0.27%) 4 |
| Memory impairment subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 |
| Essential tremor subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 |
| Parkinsonism subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 |
| Parkinson's disease subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 1 / 1489 (0.07%) 1 |
| Spastic paralysis subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 |
| Torticollis subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 |
| Tremor subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 10 / 1489 (0.67%) 10 |
| Ageusia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 |
| Analgesia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 |
| Aphonia subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 6 / 1489 (0.40%) 6 |
| Balance disorder subjects affected / exposed occurrences (all) | 35 / 1449 (2.42%) 35 | 35 / 1489 (2.35%) 35 |

| | | |
|-----------------------------|-------------------|-------------------|
| Confusional state | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 2 / 1489 (0.13%) |
| occurrences (all) | 4 | 2 |
| Coordination abnormal | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dizziness | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 8 / 1489 (0.54%) |
| occurrences (all) | 7 | 8 |
| Dizziness postural | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dysaesthesia | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dysgeusia | | |
| subjects affected / exposed | 11 / 1449 (0.76%) | 3 / 1489 (0.20%) |
| occurrences (all) | 11 | 3 |
| Hypoaesthesia | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 10 / 1489 (0.67%) |
| occurrences (all) | 10 | 10 |
| Lethargy | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Loss of consciousness | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Neuralgia | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 4 / 1489 (0.27%) |
| occurrences (all) | 5 | 4 |
| Neurological symptom | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Paraesthesia | | |
| subjects affected / exposed | 43 / 1449 (2.97%) | 23 / 1489 (1.54%) |
| occurrences (all) | 43 | 23 |

| | | |
|-----------------------------|-------------------|-------------------|
| Presyncope | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Restless legs syndrome | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) |
| occurrences (all) | 2 | 3 |
| Sensory disturbance | | |
| subjects affected / exposed | 8 / 1449 (0.55%) | 1 / 1489 (0.07%) |
| occurrences (all) | 8 | 1 |
| Somnolence | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Syncope | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Vertigo | | |
| subjects affected / exposed | 15 / 1449 (1.04%) | 17 / 1489 (1.14%) |
| occurrences (all) | 15 | 17 |
| Muscle rigidity | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Carpal tunnel syndrome | | |
| subjects affected / exposed | 35 / 1449 (2.42%) | 13 / 1489 (0.87%) |
| occurrences (all) | 35 | 13 |
| Guillain-Barre syndrome | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Nerve compression | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 2 / 1489 (0.13%) |
| occurrences (all) | 4 | 2 |
| Neuropathy peripheral | | |
| subjects affected / exposed | 17 / 1449 (1.17%) | 14 / 1489 (0.94%) |
| occurrences (all) | 17 | 14 |
| Convulsion | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | | |
|--------------------------------------|-------------------|-------------------|--|
| Epilepsy | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Insomnia | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Narcolepsy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences (all) | 0 | 3 | |
| Radiculopathy | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Sciatica | | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 11 / 1489 (0.74%) | |
| occurrences (all) | 10 | 11 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) | |
| occurrences (all) | 3 | 3 | |
| Anaemia macrocytic | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 1 | 2 | |
| Coagulopathy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 1 | 2 | |
| Increased tendency to bruise | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 4 / 1489 (0.27%) | |
| occurrences (all) | 0 | 4 | |
| Blood disorder | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 3 | 2 | |
| Haemolytic anaemia | | | |

| | | | |
|-------------------------------|------------------|------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Chronic lymphocytic leukaemia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Non-Hodgkin's lymphoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Gammopathy | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Multiple myeloma | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 1 | 2 | |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Leukocytosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Leukopenia | | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 4 / 1489 (0.27%) | |
| occurrences (all) | 4 | 4 | |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Ear and labyrinth disorders | | | |
| Cholesteatoma | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|-------------------------------|-------------------|-------------------|--|
| Ear pain | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) | |
| occurrences (all) | 2 | 3 | |
| Deafness | | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 5 / 1489 (0.34%) | |
| occurrences (all) | 6 | 5 | |
| Hearing impaired | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Meniere's disease | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Tinnitus | | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 4 / 1489 (0.27%) | |
| occurrences (all) | 7 | 4 | |
| Vertigo | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 3 | 1 | |
| Mastoid disorder | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Mastoiditis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Middle ear adhesions | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Tympanic membrane perforation | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 1 | 1 | |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 77 / 1449 (5.31%) | 64 / 1489 (4.30%) | |
| occurrences (all) | 77 | 64 | |
| Cataract congenital | | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Cataract diabetic | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cataract nuclear | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Entropion | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Corneal disorder | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Dry eye | | |
| subjects affected / exposed | 35 / 1449 (2.42%) | 49 / 1489 (3.29%) |
| occurrences (all) | 35 | 49 |
| Eye disorder | | |
| subjects affected / exposed | 38 / 1449 (2.62%) | 35 / 1489 (2.35%) |
| occurrences (all) | 38 | 35 |
| Eye pain | | |
| subjects affected / exposed | 8 / 1449 (0.55%) | 5 / 1489 (0.34%) |
| occurrences (all) | 8 | 5 |
| Eyelid disorder | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Lacrimation increased | | |
| subjects affected / exposed | 12 / 1449 (0.83%) | 7 / 1489 (0.47%) |
| occurrences (all) | 12 | 7 |
| Vitreous disorder | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Borderline glaucoma | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Glaucoma | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 21 / 1449 (1.45%) | 15 / 1489 (1.01%) |
| occurrences (all) | 21 | 15 |
| Ocular hypertension | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Conjunctival haemorrhage | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Eye haemorrhage | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Blepharitis | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 3 / 1489 (0.20%) |
| occurrences (all) | 7 | 3 |
| Conjunctivitis | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 6 / 1489 (0.40%) |
| occurrences (all) | 5 | 6 |
| Episcleritis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Eye irritation | | |
| subjects affected / exposed | 9 / 1449 (0.62%) | 8 / 1489 (0.54%) |
| occurrences (all) | 9 | 8 |
| Ocular hyperaemia | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) |
| occurrences (all) | 2 | 3 |
| Haemangioma of retina | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Blepharospasm | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) |
| occurrences (all) | 0 | 3 |
| Macular degeneration | | |
| subjects affected / exposed | 8 / 1449 (0.55%) | 5 / 1489 (0.34%) |
| occurrences (all) | 8 | 5 |
| Macular hole | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Retinal detachment | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 4 / 1489 (0.27%) |
| occurrences (all) | 4 | 4 |
| Retinal tear | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Vitreous detachment | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 4 / 1489 (0.27%) |
| occurrences (all) | 6 | 4 |
| Diabetic retinopathy | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Retinal artery occlusion | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Retinal vein occlusion | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Retinal vein thrombosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Blindness | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Diplopia | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Myopia | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) |
| occurrences (all) | 3 | 1 |
| Vision blurred | | |
| subjects affected / exposed | 12 / 1449 (0.83%) | 18 / 1489 (1.21%) |
| occurrences (all) | 12 | 18 |
| Visual acuity reduced | | |

| | | | |
|--|-------------------------|-------------------------|--|
| subjects affected / exposed occurrences (all) | 40 / 1449 (2.76%) 40 | 42 / 1489 (2.82%) 42 | |
| Visual impairment subjects affected / exposed occurrences (all) | 11 / 1449 (0.76%) 11 | 14 / 1489 (0.94%) 14 | |
| Gastrointestinal disorders | | | |
| Abdominal hernia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 4 / 1489 (0.27%) 4 | |
| Femoral hernia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Hiatus hernia subjects affected / exposed occurrences (all) | 6 / 1449 (0.41%) 6 | 5 / 1489 (0.34%) 5 | |
| Inguinal hernia subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Lumbar hernia subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Anal fissure subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 3 / 1489 (0.20%) 3 | |
| Anal pruritus subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Anorectal disorder subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Anorectal squamous cell metaplasia subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Rectal prolapse subjects affected / exposed occurrences (all) | 3 / 1449 (0.21%) 3 | 1 / 1489 (0.07%) 1 | |

| | | |
|--|------------------|------------------|
| Anal polyp | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Colonic polyp | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Gastric polyps | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Intestinal polyp | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Rectal polyp | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Gingival disorder | | |
| subjects affected / exposed | 8 / 1449 (0.55%) | 5 / 1489 (0.34%) |
| occurrences (all) | 8 | 5 |
| Gingivitis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Poor dental condition | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Tooth fracture | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Toothache | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Diverticulitis | | |
| subjects affected / exposed | 7 / 1449 (0.48%) | 9 / 1489 (0.60%) |
| occurrences (all) | 7 | 9 |
| Diverticulitis intestinal haemorrhagic | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | |
|------------------------------|------------------|-------------------|
| Diverticulum | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Barrett's oesophagus | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Food poisoning | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gastric disorder | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Gastric mucosal hypertrophy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gastrointestinal disorder | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 12 / 1489 (0.81%) |
| occurrences (all) | 4 | 12 |
| Oesophageal disorder | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Haematemesis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Haematochezia | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rectal haemorrhage | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 9 / 1489 (0.60%) |
| occurrences (all) | 2 | 9 |
| Small intestinal haemorrhage | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Colitis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |

| | | |
|-------------------------------|-------------------|-------------------|
| Colitis ischaemic | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Colitis ulcerative | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gastritis | | |
| subjects affected / exposed | 12 / 1449 (0.83%) | 13 / 1489 (0.87%) |
| occurrences (all) | 12 | 13 |
| Gastrointestinal inflammation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Inflammatory bowel disease | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Oesophagitis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Proctocolitis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Reflux oesophagitis | | |
| subjects affected / exposed | 17 / 1449 (1.17%) | 18 / 1489 (1.21%) |
| occurrences (all) | 17 | 18 |
| Change of bowel habit | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 2 / 1489 (0.13%) |
| occurrences (all) | 5 | 2 |
| Constipation | | |
| subjects affected / exposed | 24 / 1449 (1.66%) | 42 / 1489 (2.82%) |
| occurrences (all) | 24 | 42 |
| Diarrhoea | | |
| subjects affected / exposed | 20 / 1449 (1.38%) | 18 / 1489 (1.21%) |
| occurrences (all) | 20 | 18 |
| Duodenogastric reflux | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | |
|--|-------------------------|-------------------------|
| Gastrooesophageal reflux disease subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 2 / 1489 (0.13%) 2 |
| Irritable bowel syndrome subjects affected / exposed occurrences (all) | 5 / 1449 (0.35%) 5 | 3 / 1489 (0.20%) 3 |
| Abdominal discomfort subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 |
| Abdominal distension subjects affected / exposed occurrences (all) | 15 / 1449 (1.04%) 15 | 11 / 1489 (0.74%) 11 |
| Abdominal mass subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 2 / 1489 (0.13%) 2 |
| Abdominal pain subjects affected / exposed occurrences (all) | 33 / 1449 (2.28%) 33 | 48 / 1489 (3.22%) 48 |
| Dyspepsia subjects affected / exposed occurrences (all) | 25 / 1449 (1.73%) 25 | 24 / 1489 (1.61%) 24 |
| Dysphagia subjects affected / exposed occurrences (all) | 3 / 1449 (0.21%) 3 | 1 / 1489 (0.07%) 1 |
| Epigastric discomfort subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 |
| Flatulence subjects affected / exposed occurrences (all) | 9 / 1449 (0.62%) 9 | 10 / 1489 (0.67%) 10 |
| Gastrointestinal pain subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 |
| Nausea subjects affected / exposed occurrences (all) | 57 / 1449 (3.93%) 57 | 51 / 1489 (3.43%) 51 |

| | | |
|-----------------------------|------------------|------------------|
| Pelvic pain | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Vomiting | | |
| subjects affected / exposed | 9 / 1449 (0.62%) | 7 / 1489 (0.47%) |
| occurrences (all) | 9 | 7 |
| Gallstone ileus | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Intestinal obstruction | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Gastric ulcer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Large intestine perforation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Haemorrhoids | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 7 / 1489 (0.47%) |
| occurrences (all) | 6 | 7 |
| Coeliac disease | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Anal cancer | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rectal cancer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Mouth ulceration | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 7 / 1489 (0.47%) |
| occurrences (all) | 3 | 7 |
| Oral pain | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |

| | | | |
|--|-------------------|-------------------|--|
| Stomatitis | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Abdominal adhesions | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Dry mouth | | | |
| subjects affected / exposed | 25 / 1449 (1.73%) | 16 / 1489 (1.07%) | |
| occurrences (all) | 25 | 16 | |
| Dry throat | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Lip dry | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Salivary gland cyst | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Salivary gland disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Ageusia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Glossitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Tongue disorder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Skin and subcutaneous tissue disorders | | | |
| Acne | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 4 / 1489 (0.27%) | |
| occurrences (all) | 0 | 4 | |
| Actinic keratosis | | | |

| | | |
|-----------------------------|-------------------|-------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Alopecia | | |
| subjects affected / exposed | 80 / 1449 (5.52%) | 93 / 1489 (6.25%) |
| occurrences (all) | 80 | 93 |
| Alopecia areata | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Basal cell carcinoma | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Basal cell naevus syndrome | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Blister | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) |
| occurrences (all) | 2 | 2 |
| Bowen's disease | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Cellulitis | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 4 / 1489 (0.27%) |
| occurrences (all) | 2 | 4 |
| Dermal cyst | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 5 / 1489 (0.34%) |
| occurrences (all) | 6 | 5 |
| Dermatomyositis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dry skin | | |
| subjects affected / exposed | 27 / 1449 (1.86%) | 28 / 1489 (1.88%) |
| occurrences (all) | 27 | 28 |
| Eczema | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 18 / 1489 (1.21%) |
| occurrences (all) | 6 | 18 |
| Erythema | | |

| | | |
|-----------------------------|------------------------|------------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Erythema multiforme | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 3 / 1489 (0.20%) |
| occurrences (all) | 5 | 3 |
| Erythema nodosum | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hair colour changes | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hair disorder | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 11 / 1489 (0.74%) |
| occurrences (all) | 5 | 11 |
| Hirsutism | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 12 / 1489 (0.81%) |
| occurrences (all) | 6 | 12 |
| Hyperhidrosis | | |
| subjects affected / exposed | 25 / 1449 (1.73%) | 18 / 1489 (1.21%) |
| occurrences (all) | 25 | 18 |
| Lichen planus | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Lichen sclerosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Morphoea | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Nail disorder | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 13 / 1489 (0.87%) |
| occurrences (all) | 6 | 13 |
| Night sweats | | |
| subjects affected / exposed | 310 / 1449 (21.39%) | 341 / 1489 (22.90%) |
| occurrences (all) | 310 | 341 |

| | | |
|-----------------------------|-------------------|-------------------|
| Onychoclasia | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 16 / 1489 (1.07%) |
| occurrences (all) | 6 | 16 |
| Periorbital oedema | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Photosensitivity reaction | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) |
| occurrences (all) | 2 | 2 |
| Pigmentation disorder | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) |
| occurrences (all) | 2 | 3 |
| Pruritus | | |
| subjects affected / exposed | 22 / 1449 (1.52%) | 38 / 1489 (2.55%) |
| occurrences (all) | 22 | 38 |
| Pruritus generalised | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Psoriasis | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 3 / 1489 (0.20%) |
| occurrences (all) | 6 | 3 |
| Rash | | |
| subjects affected / exposed | 26 / 1449 (1.79%) | 37 / 1489 (2.48%) |
| occurrences (all) | 26 | 37 |
| Rash erythematous | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Rash pruritic | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Rash scarlatiniform | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rosacea | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 6 / 1489 (0.40%) |
| occurrences (all) | 1 | 6 |

| | | |
|---|-------------------|-------------------|
| Scar | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Scar pain | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 4 / 1489 (0.27%) |
| occurrences (all) | 1 | 4 |
| Skin atrophy | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Skin cancer | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Skin disorder | | |
| subjects affected / exposed | 12 / 1449 (0.83%) | 12 / 1489 (0.81%) |
| occurrences (all) | 12 | 12 |
| Skin lesion | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Skin mass | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 2 / 1489 (0.13%) |
| occurrences (all) | 3 | 2 |
| Skin swelling | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 6 / 1489 (0.40%) |
| occurrences (all) | 2 | 6 |
| Skin ulcer | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) |
| occurrences (all) | 3 | 1 |
| Skin warm | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Superficial spreading melanoma stage unspecified | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Swelling face | | |

| | | | |
|-----------------------------|------------------|-------------------|--|
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 1 | 2 | |
| Telangiectasia | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences (all) | 0 | 3 | |
| Urticaria | | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 11 / 1489 (0.74%) | |
| occurrences (all) | 6 | 11 | |
| Varicella | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Vitiligo | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Renal and urinary disorders | | | |
| Bladder disorder | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Bladder prolapse | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Calculus bladder | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Chromaturia | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Cystitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 1 | 1 | |
| Dysuria | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 6 / 1489 (0.40%) | |
| occurrences (all) | 2 | 6 | |
| Haematuria | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 2 | 1 | |

| | | |
|---|-----------------------|-------------------------|
| Haemorrhage urinary tract subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 |
| Micturition disorder subjects affected / exposed occurrences (all) | 7 / 1449 (0.48%) 7 | 16 / 1489 (1.07%) 16 |
| Micturition urgency subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 0 / 1489 (0.00%) 0 |
| Nephrolithiasis subjects affected / exposed occurrences (all) | 3 / 1449 (0.21%) 3 | 0 / 1489 (0.00%) 0 |
| Nocturia subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 |
| Pollakiuria subjects affected / exposed occurrences (all) | 6 / 1449 (0.41%) 6 | 10 / 1489 (0.67%) 10 |
| Polyuria subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 |
| Renal colic subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 2 / 1489 (0.13%) 2 |
| Renal cyst subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 |
| Renal disorder subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 |
| Renal failure chronic subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 |
| Renal tubular acidosis subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 |

| | | | |
|---|-----------------------|-------------------------|--|
| Stress urinary incontinence subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 3 / 1489 (0.20%) 3 | |
| Urethral stenosis subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 | |
| Urinary incontinence subjects affected / exposed occurrences (all) | 6 / 1449 (0.41%) 6 | 15 / 1489 (1.01%) 15 | |
| Urinary tract infection subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Endocrine disorders | | | |
| Adrenal adenoma subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Adrenal carcinoma subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Adrenal disorder subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Adrenal mass subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Diabetes mellitus subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 0 / 1489 (0.00%) 0 | |
| Type 2 diabetes mellitus subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 4 / 1489 (0.27%) 4 | |
| Hypoparathyroidism subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Parathyroid disorder | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Goitre | | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 5 / 1489 (0.34%) | |
| occurrences (all) | 6 | 5 | |
| Hyperthyroidism | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Hypothyroidism | | | |
| subjects affected / exposed | 12 / 1449 (0.83%) | 16 / 1489 (1.07%) | |
| occurrences (all) | 12 | 16 | |
| Thyroid cyst | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 2 | 2 | |
| Thyroid disorder | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 2 | 2 | |
| Musculoskeletal and connective tissue disorders | | | |
| Bone erosion | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Exostosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 1 | 1 | |
| Jaw disorder | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Osteitis deformans | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Osteonecrosis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Osteopenia | | | |

| | | |
|-----------------------------|--------------------|-------------------|
| subjects affected / exposed | 11 / 1449 (0.76%) | 4 / 1489 (0.27%) |
| occurrences (all) | 11 | 4 |
| Osteoporosis | | |
| subjects affected / exposed | 106 / 1449 (7.32%) | 71 / 1489 (4.77%) |
| occurrences (all) | 106 | 71 |
| Osteoporosis postmenopausal | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Pain in jaw | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Spinal disorder | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| CREST syndrome | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Morphoea | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Polymyalgia rheumatica | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 2 / 1489 (0.13%) |
| occurrences (all) | 5 | 2 |
| Scleroderma | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Sjogren's syndrome | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Ankle fracture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Clavicle fracture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Fibula fracture | | |

| | | |
|-----------------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Foot fracture | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) |
| occurrences (all) | 2 | 2 |
| Forearm fracture | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Fractured coccyx | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hand fracture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Hip fracture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Humerus fracture | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Lower limb fracture | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Osteoporotic fracture | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) |
| occurrences (all) | 3 | 1 |
| Pathological fracture | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Radius fracture | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rib fracture | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Spinal fracture | | |

| | | | |
|-----------------------------|---------------------|---------------------|--|
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 2 | 2 | |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Upper limb fracture | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Wrist fracture | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 3 | 1 | |
| Ankylosing spondylitis | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 2 | 2 | |
| Arthralgia | | | |
| subjects affected / exposed | 842 / 1449 (58.11%) | 748 / 1489 (50.24%) | |
| occurrences (all) | 842 | 748 | |
| Arthritis | | | |
| subjects affected / exposed | 52 / 1449 (3.59%) | 50 / 1489 (3.36%) | |
| occurrences (all) | 52 | 50 | |
| Arthritis bacterial | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 1 | 1 | |
| Arthritis infective | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Arthritis reactive | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Arthropathy | | | |
| subjects affected / exposed | 11 / 1449 (0.76%) | 9 / 1489 (0.60%) | |
| occurrences (all) | 11 | 9 | |
| Floating patella | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |

| | | |
|--|-------------------|-------------------|
| Haemarthrosis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Joint dislocation | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Joint effusion | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Joint stiffness | | |
| subjects affected / exposed | 74 / 1449 (5.11%) | 37 / 1489 (2.48%) |
| occurrences (all) | 74 | 37 |
| Joint swelling | | |
| subjects affected / exposed | 18 / 1449 (1.24%) | 17 / 1489 (1.14%) |
| occurrences (all) | 18 | 17 |
| Neuropathic arthropathy | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Osteoarthritis | | |
| subjects affected / exposed | 67 / 1449 (4.62%) | 53 / 1489 (3.56%) |
| occurrences (all) | 67 | 53 |
| Palindromic rheumatism | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Periarthritis | | |
| subjects affected / exposed | 9 / 1449 (0.62%) | 4 / 1489 (0.27%) |
| occurrences (all) | 9 | 4 |
| Rheumatoid arthritis | | |
| subjects affected / exposed | 15 / 1449 (1.04%) | 12 / 1489 (0.81%) |
| occurrences (all) | 15 | 12 |
| Rotator cuff syndrome | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Senile ankylosing vertebral hyperostosis | | |

| | | |
|----------------------------------|--------------------|--------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Spinal osteoarthritis | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 6 / 1489 (0.40%) |
| occurrences (all) | 4 | 6 |
| Spondylitis | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) |
| occurrences (all) | 2 | 3 |
| Temporomandibular joint syndrome | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Fibromyalgia | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Muscle atrophy | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Muscle spasms | | |
| subjects affected / exposed | 26 / 1449 (1.79%) | 108 / 1489 (7.25%) |
| occurrences (all) | 26 | 108 |
| Myalgia | | |
| subjects affected / exposed | 124 / 1449 (8.56%) | 106 / 1489 (7.12%) |
| occurrences (all) | 124 | 106 |
| Periodic limb movement disorder | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Torticollis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Trismus | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 1 / 1489 (0.07%) |
| occurrences (all) | 3 | 1 |
| Cervical spinal stenosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Foot deformity | | |

| | | |
|---------------------------------|-------------------|--------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Intervertebral disc compression | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Intervertebral disc disorder | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Intervertebral disc protrusion | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 7 / 1489 (0.47%) |
| occurrences (all) | 6 | 7 |
| Lumbar spine flattening | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Sciatica | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Scoliosis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Axillary mass | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Back disorder | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Back pain | | |
| subjects affected / exposed | 82 / 1449 (5.66%) | 101 / 1489 (6.78%) |
| occurrences (all) | 82 | 101 |
| Dupuytren's contracture | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Limb discomfort | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Musculoskeletal chest pain | | |

| | | |
|-----------------------------|--------------------|-------------------|
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Musculoskeletal pain | | |
| subjects affected / exposed | 100 / 1449 (6.90%) | 95 / 1489 (6.38%) |
| occurrences (all) | 100 | 95 |
| Musculoskeletal stiffness | | |
| subjects affected / exposed | 19 / 1449 (1.31%) | 18 / 1489 (1.21%) |
| occurrences (all) | 19 | 18 |
| Neck mass | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Neck pain | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Pain in extremity | | |
| subjects affected / exposed | 101 / 1449 (6.97%) | 80 / 1489 (5.37%) |
| occurrences (all) | 101 | 80 |
| Plantar fasciitis | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 5 / 1489 (0.34%) |
| occurrences (all) | 4 | 5 |
| Bunion | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Bursitis | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 11 / 1489 (0.74%) |
| occurrences (all) | 2 | 11 |
| Synovial cyst | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Cartilage injury | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Costochondritis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Tendonitis | | |

| | | | |
|-------------------------------------|-------------------|------------------|--|
| subjects affected / exposed | 18 / 1449 (1.24%) | 8 / 1489 (0.54%) | |
| occurrences (all) | 18 | 8 | |
| Tenosynovitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Trigger finger | | | |
| subjects affected / exposed | 10 / 1449 (0.69%) | 4 / 1489 (0.27%) | |
| occurrences (all) | 10 | 4 | |
| Breast cancer | | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 6 / 1489 (0.40%) | |
| occurrences (all) | 3 | 6 | |
| Infections and infestations | | | |
| Subacute sclerosing panencephalitis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Bacterial infection | | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 5 | 2 | |
| Breast cellulitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) | |
| occurrences (all) | 0 | 2 | |
| Folliculitis | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) | |
| occurrences (all) | 0 | 1 | |
| Helicobacter gastritis | | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Helicobacter infection | | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Lyme disease | | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) | |
| occurrences (all) | 0 | 3 | |

| | | |
|-----------------------------|-------------------|-------------------|
| Staphylococcal infection | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Fungal infection | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Oral candidiasis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) |
| occurrences (all) | 0 | 3 |
| Pneumonia cryptococcal | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Vulvovaginal candidiasis | | |
| subjects affected / exposed | 9 / 1449 (0.62%) | 42 / 1489 (2.82%) |
| occurrences (all) | 9 | 42 |
| Acute sinusitis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 3 / 1489 (0.20%) |
| occurrences (all) | 1 | 3 |
| Arthritis infective | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Breast abscess | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Bronchiectasis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Chronic sinusitis | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Cystitis | | |
| subjects affected / exposed | 14 / 1449 (0.97%) | 14 / 1489 (0.94%) |
| occurrences (all) | 14 | 14 |
| Diverticulitis | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 5 / 1489 (0.34%) |
| occurrences (all) | 4 | 5 |

| | | |
|-----------------------------------|------------------|-------------------|
| Eye infection | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Furuncle | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Gastroenteritis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Hordeolum | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Incision site infection | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Labyrinthitis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Liver abscess | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Localised infection | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Lower respiratory tract infection | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 14 / 1489 (0.94%) |
| occurrences (all) | 5 | 14 |
| Lung infection | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Mastitis | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Otitis externa | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | |
|-----------------------------|------------------|------------------|
| Otitis media | | |
| subjects affected / exposed | 4 / 1449 (0.28%) | 4 / 1489 (0.27%) |
| occurrences (all) | 4 | 4 |
| Paronychia | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 3 / 1489 (0.20%) |
| occurrences (all) | 0 | 3 |
| Pharyngitis | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 7 / 1489 (0.47%) |
| occurrences (all) | 2 | 7 |
| Pneumonia | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 0 / 1489 (0.00%) |
| occurrences (all) | 5 | 0 |
| Post procedural infection | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 3 / 1489 (0.20%) |
| occurrences (all) | 3 | 3 |
| Respiratory tract infection | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Rhinitis | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Sepsis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Sialoadenitis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Sinusitis | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 0 / 1489 (0.00%) |
| occurrences (all) | 2 | 0 |
| Skin infection | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 4 / 1489 (0.27%) |
| occurrences (all) | 1 | 4 |
| Tonsillitis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |

| | | |
|-----------------------------------|-------------------|-------------------|
| Tooth abscess | | |
| subjects affected / exposed | 5 / 1449 (0.35%) | 7 / 1489 (0.47%) |
| occurrences (all) | 5 | 7 |
| Upper respiratory tract infection | | |
| subjects affected / exposed | 6 / 1449 (0.41%) | 5 / 1489 (0.34%) |
| occurrences (all) | 6 | 5 |
| Urinary tract infection | | |
| subjects affected / exposed | 23 / 1449 (1.59%) | 32 / 1489 (2.15%) |
| occurrences (all) | 23 | 32 |
| Wound infection | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 1 / 1489 (0.07%) |
| occurrences (all) | 1 | 1 |
| Mycobacterial infection | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Tuberculosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Toxoplasmosis | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hepatitis viral | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Herpes simplex | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Herpes zoster | | |
| subjects affected / exposed | 11 / 1449 (0.76%) | 13 / 1489 (0.87%) |
| occurrences (all) | 11 | 13 |
| Influenza | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 14 / 1489 (0.94%) |
| occurrences (all) | 2 | 14 |
| Post viral fatigue syndrome | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |

| | | | |
|--|-------------------------|-----------------------|--|
| Vestibular neuronitis subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 2 / 1489 (0.13%) 2 | |
| Viral infection subjects affected / exposed occurrences (all) | 7 / 1449 (0.48%) 7 | 8 / 1489 (0.54%) 8 | |
| Metabolism and nutrition disorders | | | |
| Renal tubular acidosis subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Decreased appetite subjects affected / exposed occurrences (all) | 10 / 1449 (0.69%) 10 | 6 / 1489 (0.40%) 6 | |
| Increased appetite subjects affected / exposed occurrences (all) | 2 / 1449 (0.14%) 2 | 0 / 1489 (0.00%) 0 | |
| Weight fluctuation subjects affected / exposed occurrences (all) | 6 / 1449 (0.41%) 6 | 2 / 1489 (0.13%) 2 | |
| Bone metabolism disorder subjects affected / exposed occurrences (all) | 0 / 1449 (0.00%) 0 | 1 / 1489 (0.07%) 1 | |
| Osteopenia subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 0 / 1489 (0.00%) 0 | |
| Osteoporosis subjects affected / exposed occurrences (all) | 4 / 1449 (0.28%) 4 | 2 / 1489 (0.13%) 2 | |
| Diabetic foot subjects affected / exposed occurrences (all) | 1 / 1449 (0.07%) 1 | 1 / 1489 (0.07%) 1 | |
| Fluid retention subjects affected / exposed occurrences (all) | 3 / 1449 (0.21%) 3 | 5 / 1489 (0.34%) 5 | |
| Hyperkalaemia | | | |

| | | |
|--------------------------------------|-------------------|-------------------|
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hypokalaemia | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 1 / 1489 (0.07%) |
| occurrences (all) | 2 | 1 |
| Hyponatraemia | | |
| subjects affected / exposed | 3 / 1449 (0.21%) | 0 / 1489 (0.00%) |
| occurrences (all) | 3 | 0 |
| Diabetes mellitus | | |
| subjects affected / exposed | 21 / 1449 (1.45%) | 13 / 1489 (0.87%) |
| occurrences (all) | 21 | 13 |
| Diabetes mellitus inadequate control | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Hypoglycaemia | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Type 1 diabetes mellitus | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Type 2 diabetes mellitus | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 4 / 1489 (0.27%) |
| occurrences (all) | 0 | 4 |
| Haemochromatosis | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 2 / 1489 (0.13%) |
| occurrences (all) | 0 | 2 |
| Iron deficiency anaemia | | |
| subjects affected / exposed | 2 / 1449 (0.14%) | 3 / 1489 (0.20%) |
| occurrences (all) | 2 | 3 |
| Iron overload | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Hypercholesterolaemia | | |
| subjects affected / exposed | 47 / 1449 (3.24%) | 11 / 1489 (0.74%) |
| occurrences (all) | 47 | 11 |
| Hyperlipidaemia | | |

| | | |
|-----------------------------|------------------|------------------|
| subjects affected / exposed | 3 / 1449 (0.21%) | 8 / 1489 (0.54%) |
| occurrences (all) | 3 | 8 |
| Goitre | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hypothyroidism | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gout | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Folate deficiency | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Multi-vitamin deficiency | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 0 / 1489 (0.00%) |
| occurrences (all) | 1 | 0 |
| Vitamin B12 deficiency | | |
| subjects affected / exposed | 0 / 1449 (0.00%) | 1 / 1489 (0.07%) |
| occurrences (all) | 0 | 1 |
| Vitamin B6 deficiency | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |
| Vitamin D deficiency | | |
| subjects affected / exposed | 1 / 1449 (0.07%) | 2 / 1489 (0.13%) |
| occurrences (all) | 1 | 2 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|---|
| 14 February 2005 | Transfer from CTC to CTA |
| 23 September 2005 | <ul style="list-style-type: none"> - New steering committee members listed. - New GCP statement. - Clarification of roles of CR-UK and QM. - Addition of any previous breast cancer and history of gluten intolerance to exclusion criteria. - Clarification of acceptable management of menopausal symptoms. - Reference added to million women study. - Clarifications of lines of reporting for AEs and SAEs. - Clarification that the study nurse can consent patients in the study. - Clarification of requirements for blood samples and pathology specimens. - Development of new information flyer and poster on the DCIS arm of the trial. |
| 29 September 2006 | <ul style="list-style-type: none"> - Details of the new IBIS-II DCIS sites have been listed together with the names of the principal investigators. - A new joint patient information sheet (PIS) was developed for these patients who will be approached to enter the IBIS-II DCIS and/or BASO DCIS (DCIIS) trial. Each of these patients will now receive the IBIS-II DCIS PIS, the BASO DCIS PIS and the new joint IBIS-II/DCIS PIS. - Prof. Ian Weller has become chairman of the IBIS-II IDMC and Prof. Abdel Babiker has joined the IDMC. |
| 31 January 2007 | <ul style="list-style-type: none"> - The details of the new IBIS-II DCIS sites have been listed together with the names of the principal investigators. - The reference to 'bone pain' in section 10 of the IBIS-II DCIS PIS was clarified and changed to 'joint pain and stiffness' (I.e. Arthralgia). - The reference to CERES in section 2 was deleted. - Section 9 of IBIS-II DCIS PIS: 'What are the alternatives for diagnosis or treatment?' was reworded slightly: 'If you choose not to take part in the study, your treating clinician will advise whether you should take Tamoxifen or another appropriate treatment. Alternatively you may wish to have no additional treatment but rely on surgery and radiotherapy if recommended by your clinician.' |
| 21 May 2007 | <ul style="list-style-type: none"> - The details of the new IBIS-II DCIS sites have been listed together with the names of the principal investigators. - New eligibility criteria have been added to the protocol: 1) IBIS-I participants off trial therapy for at least 5 years; 2) Patients who have Paget's disease with underlying DCIS. - Carpal Tunnel Syndrome and ischaemic cardiovascular events have been added as a possible side effect of Anastrozole to the protocol and Carpal Tunnel Syndrome is now included in the PIS as a possible side effect. - Some of the members of the IDMC changed. These have been reflected in the protocol. - Notification of extension of recruitment to the end of 2010. |
| 30 April 2008 | <ul style="list-style-type: none"> - Creation of a questionnaire to follow up participants who are no longer on the trial. The questionnaire will only be sent out to participants who have agreed to be contacted by the IBIS-II CCO. It aims to record any medical conditions the women are experiencing and the severity of those conditions. It will also record any medication that the participants are taking. |

| | |
|------------------|---|
| 04 August 2008 | <p>Women who have had a locally excised DCIS are only eligible if the Oestrogen Receptor and/or Progesterone Receptor (ER and/or PgR) status is known and is greater than or equal to 5% positive cells. The protocol previously stated that the ER and PgR status should be greater than 5% positive cells.</p> <p>Clarification of one of entry criteria. The protocol states that patients are eligible if they have had surgery to remove an ER or PgR +ve DCIS within the last six months. The protocol was previously unclear as to whether a patient was eligible for the trial six months from diagnosis or six months from surgery.</p> <p>Inclusion of a paragraph to say that where it is not possible for a patient to be randomized within this six month period between surgery for DCIS, due to unavailability of an appointment for baseline scans, the patient can join the trial provided that this is no longer than an additional three months. However, this must be authorised by the IBIS-II Central Coordinating Office (CCO). This has been added as we have found that many hospitals have long waiting lists for scans and the delays have had a knock-on effect in delaying randomization.</p> <p>Reference to the BASO DCIS II trial has been deleted as this trial is now closed.</p> <p>The protocol now states that two spinal x-rays in one lateral dimension are required to assess low trauma vertebral fractures. Due to a previous error the protocol had stated that only one x-ray was required.</p> <p>Clarified the issue of micro invasion; the protocol now states that patients with a multiple focus of micro invasion are eligible to join IBIS-II as long as each focus is less than 1mm in size. The protocol had previously stated that only a single focus of micro invasion was eligible for the trial.</p> <p>The protocol now states that the diagnosis of breast cancer is not an SAE as this is a study end point, included to comply with GCP.</p> <p>The end point of the trial has been defined as being the last participants' last visit.</p> |
| 13 March 2009 | <p>Changes to the age limits in the entry criteria for the DCIS trial in order to include more time to receive the test results for the trial. The age limits are currently 40-70 has been widened to +/-24 months of this range. However participants who are under 40 or over 70 can only enter on the agreement of the IBIS-II Steering Group co-chairmen.</p> <p>Also in order to include more time to receive the test results, an increase the time limit between scans and randomization. The entry criteria now states that: 1. If there is a delay in receiving the test results of a mammogram an extension of up to 6 months may be obtained with prior approval from one of the IBIS II Steering Group co-chairmen. 2. If there is a delay in receiving the test results of a DXA scan an extension of up to 6 months may be obtained with prior approval from one of the IBIS II Steering Group co-chairmen. 3. If there is a delay in receiving the test results of a spinal x-ray an extension of up to 12 months may be obtained with prior approval from one of the IBIS II Steering Group co-chairmen.</p> <p>Additional points added to the inclusion criteria: Patients who have had atypical hyperplasia or lobular carcinoma in-situ to be randomized into the DCIS trial plus 'In cases where the deep margin is less than 1mm, due to the proximity of the chest wall, the patient may be eligible if the clinicians involved in her care agree that the whole of the DCIS has been excised'. Removal of sentence from the exclusion criteria: If a participant is osteoporotic they can enter the trial as long as their T-score is more than minus four and they have no more than two low trauma vertebral fractures. In either case they must take bisphosphonate treatment and have regular DXA scans. The protocol had previously said 'The results of the scans must be provided to the trial, as for women in the IBIS-II Prevention bone sub-protocol.' Clarification to the entry criteria for the Quick score and H-score measures of ER/PR positivity.</p> |
| 30 June 2009 | <ul style="list-style-type: none"> - Clarifications to the entry criteria of the DCIS protocol; osteoporotic women with T-scores greater than or equal to -4 (T-score \geq -4) are eligible for the DCIS trial. - Letter and reminder letter to accompany the IBIS-II annual questionnaire. - The IBIS-II CCO has been in contact with AstraZeneca regarding the distribution of updates of the Investigator Brochure (IB) to the IBIS-II sites. It has been agreed that instead of distributing hardcopy updates of the IB the IBIS-II team will now send electronic copies of the Summary of Product Characteristics (SmPC) instead. |
| 10 December 2009 | <ul style="list-style-type: none"> - New secondary labelling and distribution company |

| | |
|------------------|---|
| 11 January 2011 | <ul style="list-style-type: none"> - Addition of any history of lactose intolerance as an exclusion criterion. - Extension to the reporting of SAEs to cover the entire duration of the trial as requested by AZ. - Revision of the participant information sheet and consent forms specifically on frequency of mammogram and procedures for sending films, clarification that data may be obtained via NHS registries, and time to end of recruitment. - Revision of the post-treatment follow-up annual questionnaire. - Numerous non-substantial amendments to both the DCIS protocol and related study documents. |
| 28 February 2012 | <ul style="list-style-type: none"> - Notification to MHRA that Penn Pharmaceuticals will manufacture Tamoxifen placebo (replacing AZ) |
| 26 June 2014 | <ul style="list-style-type: none"> • Information on reporting of SAEs via data received from NHS registries, • Clarification of cancers that should not be reported as SAEs (but AEs), • A new common side effect which has been listed in the SmPC for Arimidex • A change of a Steering Committee member. |
| 30 June 2017 | <p>Change in contact person for sponsor</p> <p>Protocol changes to reflect end of active treatment period (reduced sample size and supporting power calculation to meet primary objective, streamlined participant data collection questionnaires to focus on primary and unmet secondary objectives and simplified safety reporting procedures).</p> <p>Central storage of UK consent forms at trial coordinating office to support information requests for events identified by national registries (HES, ONS).</p> <p>Clarification of RSI control.</p> <p>Newsletter for IBIS-II participants with study updates.</p> <p>Update in trial oversight committee structures.</p> <p>Change in codebreak procedure to allow patient-requested codebreaks now active treatment period is complete.</p> |
| 05 December 2019 | <ul style="list-style-type: none"> - Change of Trial Steering Committee members: - Closure of all UK sites - As part of a streamlining initiative started with amendment 52, to transfer follow up to NHS digital registries only - Reduced Safety reporting - Early closure of study in Italy - Clarification of consent process for collection and storage of patient identifiable information - Section added to revised protocol giving specific reference to ongoing section 251 CAG support |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This CTIMP trial which recruited between 03 Mar 2003 and 08 Feb 2012 formally ended 6 months early on 31 May 2021 (early termination).
Primary outcome analysis took place in 2016 (see publications). Data entry closed 31st May 2021.

Notes:

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/26686313>